Document:

Exhibit 10.2

 

 

WARRANT EXERCISE AGREEMENT

 

This Warrant Exercise Agreement (this “Agreement”)
is dated as of August 17, 2018 (the “Effective Date”), among Amyris, Inc., a Delaware corporation (the “Company”)
and the undersigned investor (the “Holder”).

 

WHEREAS,
reference is hereby made to that certain Securities Purchase Agreement, dated August 2, 2017 (the “Securities Purchase
Agreement”), by and among the Company and the investors party thereto (including the Holder, the “Holders”),
pursuant to which, among other things, the Holder acquired (a) a Common Stock Purchase Warrant, with an exercise price as of the
date hereof of $4.40 per share of common stock of the Company, par value $0.0001 per share (the “Common Stock”),
exercisable as of the date hereof into such aggregate number of shares of Common Stock as set forth on the signature page of the
Holder attached hereto (the “Cash Warrant”, as exercised, the “Cash Warrant Shares”) and
(b) a Common Stock Purchase Warrant, with an exercise price of $0.0001 per share of Common Stock, exercisable as of the date hereof
into such aggregate number of shares of Common Stock as set forth on the signature page of the Holder attached hereto (the “Dilution
Warrant”). Capitalized terms not defined herein shall have the meaning as set forth in the Securities Purchase Agreement
or the Cash Warrant, as applicable.

 

WHEREAS,
subject to the terms and conditions set forth in this Agreement and in reliance upon the exemption from securities registration
afforded by Section 4(a)(2) of the Securities Act of 1933, as amended (the “Securities Act”), and Rule 506(b)
of Regulation D (“Regulation D”) as promulgated by the United States Securities and Exchange Commission
(the “SEC”) under the Securities Act, as consideration for (a) the cash exercise of the Cash Warrant into the
applicable aggregate number of Cash Warrant Shares as set forth on the signature page of the Holder attached hereto (such number,
as applicable, the “Cash Warrant Share Exercise Amount”) and (b) the cancellation of the Dilution Warrant, the
Company shall issue to the Holder new Common Stock Purchase Warrants, in the form attached hereto as Exhibit A (collectively,
the “New Warrant”), initially exercisable into an aggregate of 6,343,778 shares of Common Stock (the “New
Warrant Shares”, and together with the New Warrant, the “New Securities”, and together with this Agreement,
the “Transaction Documents”).

 

WHEREAS,
concurrently herewith, the Company is entering into agreements with certain other Holders (each, an “Other Holder”)
of Common Stock Purchase Warrants issued pursuant to the Securities Purchase Agreement (each, an “Other Warrant”
and such agreements, each an “Other Agreement”) substantially in the form of this Agreement.

 

NOW, THEREFORE,
in consideration of the mutual covenants contained in this Agreement, and for other good and valuable consideration the receipt
and adequacy of which are hereby acknowledged, the Company and the Holder agree as follows:

 

1.                 
Exercise of Cash Warrant; Cancellation of Dilution Warrant.

 

     

     

    

 

(a)               
General. On the date hereof and at the Applicable Time (as defined in that certain Underwriting Agreement, dated
as of the Closing Date (as defined below) by and between the Company, B. Riley FBR, Inc., as the “Underwriter”,
and the Selling Stockholders (including Holder) listed on Schedule I thereto (the “Underwriting Agreement”))
and simultaneously with the transactions contemplated by clauses (ii) and (iii) of this Section 1(a) (the “Initial Exercise”
and the “Initial Exercise Date”) and, if a Second Exercise (as defined below) is triggered as a result of B.
Riley FBR, Inc. electing to exercise its option to purchase more shares of the Company’s Common Stock from the Holder pursuant
to the Underwriting Agreement (i) the Holder shall duly execute and deliver to the Company an irrevocable Notice of Exercise, in
the form attached hereto as Exhibit B (the “Notice of Exercise”) and, on or prior to the Delivery
Date (as defined below), shall wire, or shall cause to be wired (directly or indirectly) the payment of the aggregate exercise
price of the applicable Cash Warrant Share Exercise Amount of the Cash Warrant, as set forth on the signature page of the Holder
attached hereto, to the Company in accordance with the wire instructions of the Company (or the wire instructions of another party
designated by the Company) communicated to the Holder (or other relevant party making payment on behalf of the Holder) at least
one (1) Business Day prior to the (Y) date hereof in the case of the Initial Exercise and (Z) Second Exercise Date in case of the
Second Exercise (each such date, the “Closing Date” with regard to such exercise), in U.S. dollars and immediately
available funds, to effect the exercise of the applicable Cash Warrant Share Exercise Amount of the Cash Warrant, (ii) the Dilution
Warrant shall be deemed cancelled immediately on the Closing Date associated with the Initial Exercise Date and simultaneously
with the transactions contemplated by clauses (i) and (iii) of this Section 1(a) and, as promptly as commercially practicable after
the Effective Date, the Dilution Warrant shall be delivered to the Company at the address set forth in Section 5(h) hereof (provided,
that to the extent such Dilution Warrant was exercised, in whole or in part, on or prior to the Closing Date prior to its deemed
cancellation, such Dilution Warrant shall remain in full force and effect until the shares of Common Stock owed to the Holder in
such exercise(s) are delivered to the Holder (or its designee), as applicable), and (iii) the Company shall duly execute and issue
to the Holder the New Warrant on the Closing Date and simultaneously with the transactions contemplated by clauses (i) and (ii)
of this Section 1(a), initially exercisable into 6,343,778 New Warrant Shares (collectively, the “Closing”,
and such transactions, the “Transactions”). The Company shall deliver the New Warrant to the Holder as soon
as commercially practicable following the applicable Closing Date to the address set forth on the signature page of the Holder
attached hereto (or such other address as designated by the Holder in writing to the Company). Notwithstanding anything herein
to the contrary, if the Holder elects on its signature page to have the lock up provisions included as Annex I attached
hereto apply to the Holder, the Holder: (i) will be prohibited from selling or otherwise transferring for value the Cash Warrant
Share Exercise Amount of Cash Warrant Shares to be delivered to the Holder (or its designee) in accordance with the Notice of Exercise
during the period beginning on the applicable Closing Date and continuing to and including the date 180 days after such Closing
Date, and (ii) shall be entitled to effect the exercise of the Cash Warrant pursuant to a cashless exercise in accordance therewith
in lieu of the Holder’s obligations to exercise the Cash Warrant in cash in accordance therewith and herewith. If the Underwriter
exercises its option under the Underwriting Agreement to purchase the Optional Shares (as defined in the Underwriting Agreement),
then Holder will execute another irrevocable Notice of Exercise (a “Second Exercise”), and deliver such Notice
of Exercise to the Company (the date of such delivery, the “Second Exercise Date”) and there shall be a second
Closing as set forth in this paragraph.

 

    	 	2	 

     

    

 

(b)              
Delivery of Cash Warrant Shares. No later than the second (2nd) Trading Day after the applicable Closing Date (the
“Delivery Date”) the Company shall cause the applicable Cash Warrant Share Exercise Amount of Cash Warrant Shares
to be delivered to the Holder (or its designee) in accordance with the Cash Warrant and the deposit/withdrawal at custodian or
other delivery instructions set forth in the Notice of Exercise applicable to such exercise.

 

(c)               
Return of Certificates. As promptly as practicable after the applicable Closing Date, the Holder shall return to
the Company the certificate evidencing (i) the Dilution Warrant (or a lost warrant affidavit in form and substance satisfactory
to the Company), which shall automatically be deemed cancelled and null and void upon the consummation of the Closing; and (ii)
solely if the Cash Warrant is exercised in full pursuant to the Notice of Exercise, the Cash Warrant.

 

2.                 
Representations and Warranties of Company. Except as set forth in the Disclosure Schedules, which Disclosure Schedules
shall be deemed a part hereof and shall qualify any representation or warranty otherwise made herein to the extent of the disclosure
contained in the corresponding section of the Disclosure Schedules, the Company hereby makes the following representations and
warranties to the Holder:

 

(a)               
Organization and Standing. The Company and each of its subsidiaries is duly incorporated, validly existing, and in
good standing under the laws of the jurisdiction of its organization. Each of the Company and its subsidiaries has all requisite
power and authority to own and operate its respective properties and assets and to carry on its respective business as presently
conducted and as proposed to be conducted. The Company and each of its subsidiaries is qualified to do business as a foreign entity
in every jurisdiction in which the failure to be so qualified would have, or would reasonably be expected to have, a material adverse
effect, individually or in the aggregate, upon the business, properties, tangible and intangible assets, liabilities, operations,
prospects, financial condition or results of operation of the Company and its subsidiaries or the ability of the Company or any
of its subsidiaries to perform their respective obligations under the Transaction Documents (a “Material Adverse Effect”).

 

(b)              
Power. The Company has all requisite power to execute and deliver this Agreement, to sell and issue the New Securities
hereunder, and to carry out and perform its obligations under the terms of the Transaction Documents.

 

(c)               
Authorization. The execution, delivery, and performance of the Transaction Documents by the Company has been duly
authorized by all requisite action on the part of the Company and its officers, directors and stockholders, and this Agreement
constitutes, and the other Transaction Documents will constitute, legal, valid, and binding obligations of the Company enforceable
in accordance with their terms, except (a) as limited by applicable bankruptcy, insolvency, reorganization, moratorium, and other
laws of general application affecting enforcement of creditors’ rights generally, and (b) as limited by laws relating to
the availability of specific performance, injunctive relief or other equitable remedies (together, the “Enforceability
Exceptions”).

 

(d)              
Consents and Approvals. Except for any Current Report on Form 8-K or Notice of Exempt Offering of Securities on Form
D to be filed by the Company in connection with the transactions contemplated hereby, or except as set forth on Section 2(d) of
the Disclosure Schedules, the Company is not required to give any notice to, make any filing with, or obtain any authorization,
consent, or approval of any government or governmental agency in order to consummate the transactions contemplated by the Transaction
Documents. Assuming the accuracy of the representations of the Holder set forth herein, no consent, approval, authorization or
other order of, or registration, qualification or filing with, any court, regulatory body, administrative agency, self-regulatory
organization, stock exchange or market (including The NASDAQ Stock Market), or other governmental body is required for the execution
and delivery of the Transaction Documents, the valid issuance, sale and delivery of the New Securities to be sold pursuant to this
Agreement other than such as have been made or obtained, or for any securities filings required to be made under federal or state
securities laws applicable to the offering of the New Securities.

 

    	 	3	 

     

    

 

(e)               
Non-Contravention. The execution and delivery of the Transaction Documents, the issuance, sale and delivery of the
New Securities to be sold by the Company under this Agreement, the performance by the Company of its obligations under the Transaction
Documents and/or the consummation of the transactions contemplated thereby will not (i) conflict with, result in the breach or
violation of, or constitute (with or without the giving of notice or the passage of time or both) a violation of, or default under,
(A) any bond, debenture, note or other evidence of indebtedness, or under any lease, license, franchise, permit, indenture, mortgage,
deed of trust, loan agreement, joint venture or other agreement or instrument to which the Company or any subsidiary is a party
or by which it or its properties may be bound or affected, (B) the Company’s Restated Certificate of Incorporation, as amended
and as in effect on the date hereof (the “Certificate of Incorporation”), the Company’s Bylaws, as amended
and as in effect on the date hereof (the “Bylaws”), or the equivalent document with respect to any subsidiary,
as amended and as in effect on the date hereof, or (C) any statute or law, judgment, decree, rule, regulation, ordinance or order
of any court or governmental or regulatory body (including The NASDAQ Stock Market), governmental agency, arbitration panel or
authority applicable to the Company, any of its subsidiaries or their respective properties, except in the case of clauses (A)
and (C) for such conflicts, breaches, violations or defaults that would not be likely to have, individually or in the aggregate,
a Material Adverse Effect, or (ii) result in the creation or imposition of any lien, encumbrance, claim, security interest or restriction
whatsoever upon any of the material properties or assets of the Company or any of its subsidiaries or an acceleration of indebtedness
pursuant to any obligation, agreement or condition contained in any material bond, debenture, note or any other evidence of indebtedness
or any material indenture, mortgage, deed of trust or any other agreement or instrument to which the Company or any if its subsidiaries
is a party or by which the Company or any of its subsidiaries is bound or to which any of the property or assets of the Company
is subject. For purposes of this Section 2(e), the term “material” shall apply to agreements, understandings, instruments,
contracts or proposed transactions to which the Company is a party or by which it is bound involving obligations (contingent or
otherwise) of, or payments to, the Company in excess of $100,000 in a consecutive 12-month period.

 

(f)               
Authorization of the New Securities. The New Warrants have been duly authorized by the Company and, when duly executed
and delivered by the Company, will constitute a valid and binding agreement of the Company, enforceable against the Company in
accordance with its terms, subject to the Enforceability Exceptions. The New Warrant Shares issuable upon exercise of the New Warrants
have been, duly authorized and reserved for issuance upon exercise by all necessary corporate action and such shares, when issued
upon such exercise in accordance of the terms of the New Warrants, will be validly issued and will be fully paid and non-assessable,
and will be free of any liens or encumbrances with respect to the issuance thereof; provided, however, that the New Warrant Shares
shall be subject to restrictions on transfer under state or federal securities laws as set forth in this Agreement, or as otherwise
may be required under state or federal securities laws as set forth in this Agreement at the time a transfer is proposed. Except
as set forth on Section 2(f) of the Disclosure Schedules, the issuance and delivery of the New Warrant Shares is not subject to
preemptive, co-sale, right of first refusal or any other similar rights of the stockholders of the Company or any other Person,
or any liens or encumbrances or result in the triggering of any anti-dilution or other similar rights under any outstanding securities
of the Company.

 

    	 	4	 

     

    

 

(g)              
Registration. Assuming the accuracy of each of the representations and warranties of the Holder herein, the issuance
by the Company of the New Securities is exempt from registration under the Securities Act. The Company has prepared and filed a
registration statement (Registration No. 333-221351) (the “Registration Statement”) in conformity with the requirements
of the Securities Act, which became effective on December 1, 2017 (the “Warrant Effective Date”), including
a prospectus, dated December 5, 2017 (the “Prospectus”) for, among other things, the resale by the Holder of
the Cash Warrant Shares, and such amendments and supplements thereto as may have been required to the date of this Agreement. The
Registration Statement is effective under the Securities Act and no stop order preventing or suspending the effectiveness of the
Registration Statement or suspending or preventing the use of the Prospectus has been issued by the Commission and no proceedings
for that purpose have been instituted or, to the knowledge of the Company, are threatened by the Commission. At the time the Registration
Statement and any amendments thereto became effective and at the date of this Agreement, the Registration Statement and any amendments
thereto conformed and will conform in all material respects to the requirements of the Securities Act and did not and will not
contain any untrue statement of a material fact or omit to state any material fact required to be stated therein or necessary to
make the statements therein not misleading; and the Prospectus and any amendments or supplements thereto, at the time the Prospectus
or any amendment or supplement thereto was issued and as of the date hereof, conformed and will conform in all material respects
to the requirements of the Securities Act and did not and will not contain an untrue statement of a material fact or omit to state
a material fact necessary in order to make the statements therein, in light of the circumstances under which they were made, not
misleading. The Company was at the time of the filing of the Registration Statement eligible to use Form S-3.

 

(h)              
Capitalization. As of the date hereof, the authorized capital stock of the Company consists of (a) 250,000,000 shares
of Common Stock, 50,383,859 shares of which are issued and outstanding as of the date hereof, and (b) 5,000,000 shares of Preferred
Stock, $0.0001 par value per share, of which 22,140 shares have been designated as Series A 17.38% Convertible Preferred Stock,
105,204 shares have been designated as Series B 17.38% Convertible Preferred Stock, 20,921 shares have been designated as Series
C Convertible Preferred Stock and 15,000 shares have been designated as Series D Convertible Preferred Stock, and of which there
are no shares of Series A 17.38% Convertible Preferred Stock, 6,376.2787 shares of Series B 17.38% Convertible Preferred Stock,
no shares of Series C Convertible Preferred Stock and 12,958.21196 shares of Series D Convertible Preferred Stock issued and outstanding
as of the date hereof. All subscriptions, warrants, options, convertible securities, and other rights (contingent or other) to
purchase or otherwise acquire equity securities of the Company issued and outstanding as of the date hereof, or contracts, commitments,
understandings, or arrangements by which the Company or any of its subsidiaries is or may be obligated to issue shares of capital
stock, or securities or rights convertible or exchangeable for shares of capital stock, other than the New Securities, are as set
forth in the SEC Documents. Taking into account all rights and agreements described in the immediately preceding sentence and any
applicable anti-dilution provisions in any such agreement, immediately after the Closing and after giving effect to the consummation
of this offering of the New Securities, there will be (i) 64,040,753 shares of Common Stock issued and outstanding and (ii) a maximum
of 57,870,205 shares of Common Stock issuable upon conversion, exchange or exercise of all outstanding securities of the Company
(including, without limitation, all Common Stock Equivalents) that are convertible into, exercisable or exchangeable for, settled
in, or may be paid or repaid with, shares of Common Stock. The issued and outstanding shares of the Company’s capital stock
have been duly authorized and validly issued, are fully paid and nonassessable, have been issued in compliance with all applicable
federal and state securities laws, and were not issued in violation of or subject to any preemptive rights or other rights to subscribe
for or purchase securities. Except as set forth in Section 2(h) of the Disclosure Schedules, no holder of the Company’s capital
stock is entitled to preemptive or similar rights in connection with the issuance of the New Securities. Except as set forth in
or incorporated by reference into the SEC Documents filed with the SEC on or after December 31, 2017, but prior to the date hereof,
there are no bonds, debentures, notes or other indebtedness having general voting rights (or convertible into securities having
such rights) of the Company issued and outstanding. Except as set forth in or incorporated by reference into the SEC Documents
filed with the SEC on or after December 31, 2017, but prior to the date hereof, there are no agreements or arrangements under which
the Company or any of its subsidiaries is obligated to register the sale of any of their securities under the Securities Act. The
Company has made available to the Holder, a true, correct and complete copy of the Company’s Certificate of Incorporation
and Bylaws. From August 3, 2017 to the time of execution of this Agreement, the Company has not issued or sold any Common Stock
or Common Stock Equivalents at a price (or exercise, conversion or exchange price, as applicable) per share of Common Stock less
than $4.26, other than in respect of an Exempt Issuance.

 

    	 	5	 

     

    

 

(i)                
Legal Proceedings. Except as set forth in or incorporated by reference into the SEC Documents filed with the SEC
on or after December 31, 2017, but prior to the date hereof, there is no Proceeding before any court, governmental agency or body,
domestic or foreign, now pending or, to the knowledge of the Company, threatened against the Company or its subsidiaries wherein
an unfavorable decision, ruling or finding would reasonably be expected to, individually or in the aggregate, (i) materially adversely
affect the validity or enforceability of, or the authority or ability of the Company to perform its obligations under, this Agreement
or (ii) have a Material Adverse Effect. The Company is not a party to or subject to the provisions of any injunction, judgment,
decree or order of any court, regulatory body, administrative agency or other governmental agency or body that might have, individually
or in the aggregate, a Material Adverse Effect.

 

(j)                
No Violations. Neither the Company nor any of its subsidiaries is in violation of its respective certificate of incorporation,
bylaws or other organizational documents, or to its knowledge, is in violation of any statute or law, judgment, decree, rule, regulation,
ordinance or order of any court or governmental or regulatory body (including The NASDAQ Stock Market), governmental agency, arbitration
panel or authority applicable to the Company or any of its subsidiaries, which violation, individually or in the aggregate, would
be reasonably likely to have a Material Adverse Effect. Neither the Company nor any of its subsidiaries is in default (and there
exists no condition which, with or without the passage of time or giving of notice or both, would constitute a default) in the
performance of any bond, debenture, note or any other evidence of indebtedness in any indenture, mortgage, deed of trust or any
other material agreement or instrument to which the Company or any of its subsidiaries is a party or by which the Company or any
of its subsidiaries is bound or by which the properties of the Company are bound, which would be reasonably likely to have a Material
Adverse Effect. There has not been, and to the knowledge of the Company, there is not pending or contemplated, any investigation
by the Commission involving the Company or any current or former director or officer of the Company and the Company is not an “ineligible
issuer” pursuant to Rules 164, 405 and 433 under the Securities Act. The Company has not received any comment letter from
the Commission relating to any SEC Documents which has not been finally resolved. The Commission has not issued any stop order
or other order suspending the effectiveness of any registration statement filed by the Company under the Exchange Act or the Securities
Act.

 

    	 	6	 

     

    

 

(k)              
Listing Compliance. The Company is in compliance with the requirements of The NASDAQ Stock Market LLC for continued
listing of the Common Stock thereon and has no knowledge of any facts or circumstances that could reasonably lead to delisting
of its Common Stock from The NASDAQ Stock Market. The Company has taken no action designed to, or likely to have the effect of,
terminating the registration of the Common Stock under the Exchange Act or the listing of the Common Stock on The NASDAQ Stock
Market, nor has the Company received any notification that the Commission or The NASDAQ Stock Market is contemplating terminating
such registration or listing. The transactions contemplated by the Transaction Documents will not contravene the rules and regulations
of The NASDAQ Stock Market. The Company will comply with all requirements of The NASDAQ Stock Market with respect to the issuance
of the New Securities, including the filing of any listing notice with respect to the issuance of the New Securities.

 

(l)                
Integration; Other Issuances of Securities. Except as set forth in Section 2(l) of the Disclosure Schedules, neither
the Company nor its subsidiaries or any Affiliates, nor any Person acting on its or their behalf, has issued any shares of Common
Stock or shares of any series of preferred stock or other securities or instruments convertible into, exchangeable for or otherwise
entitling the holder thereof to acquire shares of Common Stock which would be integrated with the sale or exchange of the New Securities
to the Holder for purposes of the Securities Act or of any applicable stockholder approval provisions, including, without limitation,
under the rules and regulations of The NASDAQ Stock Market, nor will the Company or its subsidiaries or Affiliates take any action
or steps that would require registration of any of the New Securities under the Securities Act or cause the offering of the New
Securities to be integrated with other offerings if any such integration would cause the issuance of the New Securities hereunder
to fail to be exempt from registration under the Securities Act or cause the transactions contemplated hereby to contravene the
rules and regulations of The NASDAQ Stock Market. The Company is eligible to register the New Warrant Shares for resale by the
Holder using Form S-3 promulgated under the Securities Act.

 

(m)            
No General Solicitation. Neither the Company nor its subsidiaries or any Affiliates, nor any Person acting on its
or their behalf, has offered or sold any of the New Securities by any form of general solicitation or general advertising.

 

    	 	7	 

     

    

 

(n)              
No Brokers’ Fees. Except as set forth in Section 2(n) of the Disclosure Schedules, the Company has not incurred
any liability for any finder’s or broker’s fee or agent’s commission in connection with the execution and delivery
of this Agreement or the consummation of the transactions contemplated hereby.

 

(o)              
Acknowledgment Regarding Holder’s Purchase of Securities. The Company acknowledges and agrees that the Holder
is acting solely in the capacity of an arm’s length purchaser with respect to the Transaction Documents and the transactions
contemplated thereby. The Company further acknowledges that the Holder is not acting as a financial advisor or fiduciary of the
Company (or in any similar capacity) with respect to the Transaction Documents and the transactions contemplated thereby and any
advice given by the Holder or any of its representatives or agents in connection with the Transaction Documents and the transactions
contemplated thereby is merely incidental to the Holder’s purchase of the New Securities. The Company further represents
to the Holder that the Company’s decision to enter into this Agreement and the other Transaction Documents has been based
solely on the independent evaluation of the transactions contemplated hereby by the Company and its representatives.

 

(p)              
No Disqualification. No “bad actor” disqualifying event described in Rule 506(d)(1)(i)-(viii) of the
Securities Act (a “Disqualification Event”) is applicable to the Company or, to the Company’s knowledge,
any Company Covered Person, except for a Disqualification Event as to which Rule 506(d)(2)(ii–iv) or (d)(3), is applicable.
As used herein, “Company Covered Person” means, with respect to the Company as an “issuer” for purposes
of Rule 506 promulgated under the Securities Act, any Person listed in the first paragraph of Rule 506(d)(1).

 

(q)              
Disclosure. Except with respect to the material terms and conditions of the transactions contemplated by the Transaction
Documents, the Company confirms that neither it nor any other Person acting on its behalf has provided the Holder or its agents
or counsel with any information that it believes constitutes material, non-public information which will not otherwise be disclosed
in that certain Prospectus Supplement filed by the Company on August 16, 2018. All disclosure furnished by or on behalf of the
Company to the Holder in connection with this Agreement regarding the Company, its business and the transactions contemplated hereby
is true and correct in all material respects and does not contain any untrue statement of a material fact or omit to state any
material fact necessary in order to make the statements made therein, in light of the circumstances under which they were made,
not misleading. The Company acknowledges and agrees that the Holder has not made and does not make any representations or warranties
with respect to the transactions contemplated hereby other than those set forth in Article 3 hereto.

 

3.                 
Representations and Warranties of the Holder. The Holder hereby represents and warrants as of the date hereof
(and, where specified, as of the applicable Closing Date) to the Company as follows (unless as of a specific date therein, in which
case they shall be accurate as of such date):

 

(a)               
Organization; Authority. The Holder is either an individual or an entity duly incorporated or formed, validly existing
and in good standing under the laws of the jurisdiction of its incorporation or formation with full right, corporate, partnership,
limited liability company or similar power and authority to enter into and to consummate the transactions contemplated by the Transaction
Documents and otherwise to carry out its obligations hereunder and thereunder. The execution and delivery of the Transaction Documents
and performance by the Holder of the transactions contemplated by the Transaction Documents have been duly authorized by all necessary
corporate, partnership, limited liability company or similar action, as applicable, on the part of the Holder. Each Transaction
Document to which it is a party has been duly executed by the Holder, and when delivered by the Holder in accordance with the terms
hereof, will constitute the valid and legally binding obligation of the Holder, enforceable against it in accordance with its terms,
except: (i) as limited by general equitable principles and applicable bankruptcy, insolvency, reorganization, moratorium and other
laws of general application affecting enforcement of creditors’ rights generally, (ii) as limited by laws relating to the
availability of specific performance, injunctive relief or other equitable remedies and (iii) insofar as indemnification and contribution
provisions may be limited by applicable law.

 

    	 	8	 

     

    

 

(b)              
Understandings or Arrangements. The Holder is acquiring the New Securities as principal for its own account and has
no direct or indirect arrangement or understandings with any other persons to distribute or regarding the distribution of such
New Securities (this representation and warranty not limiting the Holder’s right to sell the Cash Warrant Shares pursuant
to the Registration Statement or otherwise in compliance with applicable federal and state securities laws). The Holder is acquiring
the New Securities hereunder in the ordinary course of its business. The Holder understands that the New Securities are “restricted
securities” and have not been registered under the Securities Act or any applicable state securities law and is acquiring
such New Securities as principal for his, her or its own account and not with a view to or for distributing or reselling such New
Securities or any part thereof in violation of the Securities Act or any applicable state securities law, has no present intention
of distributing any of such New Securities in violation of the Securities Act or any applicable state securities law and has no
direct or indirect arrangement or understandings with any other persons to distribute or regarding the distribution of such New
Securities in violation of the Securities Act or any applicable state securities law (this representation and warranty not limiting
the Holder’s right to sell the Cash Warrant Shares pursuant to the Registration Statement or otherwise in compliance with
applicable federal and state securities laws).

 

(c)               
Holder Status. At the time the Holder was offered the New Securities, it was, and as of the Closing Date it is, and
on each date on which it exercises any New Warrants, it will be an “accredited investor” as defined in Rule 501(a)(1),
(a)(2), (a)(3), (a)(7) or (a)(8) under the Securities Act.

 

(d)              
Experience of the Holder. The Holder, either alone or together with its representatives, has such knowledge, sophistication
and experience in business and financial matters so as to be capable of evaluating the merits and risks of the prospective investment
in the New Securities, and has so evaluated the merits and risks of such investment. The Holder is able to bear the economic risk
of an investment in the New Securities and, at the present time, is able to afford a complete loss of such investment.

 

(e)               
Access to Information. The Holder acknowledges that it has had the opportunity to review the Transaction Documents
(including all exhibits and schedules thereto) and the SEC Documents and has been afforded: (i) the opportunity to ask such questions
as it has deemed necessary of, and to receive answers from, representatives of the Company concerning the terms and conditions
of the offering of the New Securities and the merits and risks of investing in the New Securities; (ii) access to information about
the Company and its financial condition, results of operations, business, properties, management and prospects sufficient to enable
it to evaluate its investment; and (iii) the opportunity to obtain such additional information that the Company possesses or can
acquire without unreasonable effort or expense that is necessary to make an informed investment decision with respect to the investment.

 

    	 	9	 

     

    

 

(f)               
Confidentiality. Other than to other Persons party to this Agreement or to the Holder’s representatives, including,
without limitation, its officers, directors, partners, legal and other advisors, employees, agents and Affiliates, the Holder has
maintained the confidentiality of all disclosures made to it in connection with this transaction (including the existence and terms
of this transaction).

 

(g)              
General Solicitation. The Holder is not purchasing the New Securities as a result of any advertisement, article,
notice or other communication regarding the New Securities published in any newspaper, magazine or similar media or broadcast over
television or radio or presented at any seminar or, to the Holder’s knowledge, any other general solicitation or general
advertisement.

 

(h)              
Ownership of Cash Warrant and Dilution Warrant. The Holder owns the Cash Warrant and the Dilution Warrant, in each
case, free and clear of any Liens (other than the obligations pursuant to this Agreement, the Transaction Documents (as defined
in the Securities Purchase Agreement), the Underwriting Agreement, and applicable securities laws).

 

The Company acknowledges and agrees that the
representations contained in this Section 3 shall not modify, amend or affect the Holder’s right to rely on the Company’s
representations and warranties contained in this Agreement or any representations and warranties contained in any other Transaction
Document or any other document or instrument executed and/or delivered in connection with this Agreement or the consummation of
the transactions contemplated hereby. Notwithstanding the foregoing, for the avoidance of doubt, nothing contained herein shall
constitute a representation or warranty, or preclude any actions, with respect to locating or borrowing shares in order to effect
Short Sales or similar transactions in the future.

 

4.                 
Covenants.

 

(a)               
Removal of Legends. (i) The New Securities may only be disposed of in compliance with state and federal securities
laws. In connection with any transfer of New Securities other than pursuant to an effective registration statement or Rule 144,
to the Company or to an Affiliate of the Holder or in connection with a pledge as contemplated in Section 4(b), the Company may
require the transferor thereof to provide to the Company an opinion of counsel selected by the transferor and reasonably acceptable
to the Company, the form and substance of which opinion shall be reasonably satisfactory to the Company, to the effect that such
transfer does not require registration of such transferred New Securities under the Securities Act. The Holder agrees to the imprinting,
so long as is required by this Section 4(a), of a legend on any of the New Securities in the following form:

 

    	 	10	 

     

    

 

NEITHER THIS SECURITY NOR THE SECURITIES INTO WHICH THIS
SECURITY IS EXERCISABLE HAS BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE
IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”),
AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR
PURSUANT TO AN AVAILABLE EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT
AND IN ACCORDANCE WITH APPLICABLE STATE SECURITIES LAWS. THIS SECURITY AND THE SECURITIES ISSUABLE UPON EXERCISE OF THIS SECURITY
MAY BE PLEDGED IN CONNECTION WITH A BONA FIDE MARGIN ACCOUNT WITH A REGISTERED BROKER-DEALER OR OTHER LOAN WITH A FINANCIAL INSTITUTION
THAT IS AN “ACCREDITED INVESTOR” AS DEFINED IN RULE 501(a) UNDER THE SECURITIES ACT OR OTHER LOAN SECURED BY SUCH SECURITIES.

 

(ii)       The Company acknowledges and agrees
that the Holder may from time to time pledge pursuant to a bona fide margin agreement with a registered broker-dealer or grant
a security interest in some or all of the New Securities to a financial institution that is an “accredited investor”
as defined in Rule 501(a) under the Securities Act and, if required under the terms of such arrangement, the Holder may transfer
pledged or secured New Securities to the pledgees or secured parties. Such a pledge or transfer would not be subject to approval
of the Company and no legal opinion of legal counsel of the pledgee, secured party or pledgor shall be required in connection therewith.
Further, no notice shall be required of such pledge. At the Holder’s expense, the Company will execute and deliver such reasonable
documentation as a pledgee or secured party of New Securities may reasonably request in connection with a pledge or transfer of
the New Securities.

 

(iii)       Certificates evidencing the New
Securities shall not contain any legend: (A) while a registration statement covering the resale of such security is effective under
the Securities Act, (B) following any sale of such New Securities pursuant to Rule 144, (C) if such New Securities are eligible
for sale under Rule 144, or (D) if such legend is not required under applicable requirements of the Securities Act (including judicial
interpretations and pronouncements issued by the staff of the Commission). The Company shall cause its counsel to issue a legal
opinion to the Transfer Agent promptly if required by the Transfer Agent or requested by the Holder to effect the removal of the
legend hereunder. If all or a portion of the New Warrant is exercised at a time when there is an effective registration statement
to cover the resale of the applicable New Warrant Shares, or if such New Warrant Shares may be sold under Rule 144 or if such legend
is not otherwise required under applicable requirements of the Securities Act (including judicial interpretations and pronouncements
issued by the staff of the Commission) then such New Warrant Shares shall be issued free of all legends. The Company agrees that
following such time as such legend is no longer required under this Section 4(a) and upon the request of the Holder, the Company
will, no later than two Trading Days following the delivery by the Holder to the Transfer Agent (with simultaneous notice to the
Company pursuant to Section 5(h) hereof) of a certificate representing New Warrant Shares issued with a restrictive legend (such
second Trading Day, the “Legend Removal Date”), cause to be delivered to the Holder such shares that are free
from all restrictive and other legends by crediting the account of the Holder's prime broker with the Depository Trust Company
System as directed by the Holder. The Company may not make any notation on its records or give instructions to the Transfer Agent
that enlarge the restrictions on transfer set forth in this Section 4(a). New Warrant Shares subject to legend removal hereunder
shall be transmitted by the Transfer Agent to the Holder by crediting the account of the Holder’s prime broker with the Depository
Trust Company System as directed by the Holder.

 

    	 	11	 

     

    

 

(iv)       In addition to the Holder’s
other available remedies, the Company shall pay to the Holder, in cash, (A) as partial liquidated damages and not as a penalty,
for each $1,000 of New Warrant Shares (based on the VWAP of the Common Stock on the date such New Securities are submitted to the
Transfer Agent) delivered for removal of the restrictive legend and subject to Section 4(a)(ii), $10 per Trading Day (increasing
to $20 per Trading Day five (5) Trading Days after such damages have begun to accrue) for each Trading Day commencing one Trading
Day after the Legend Removal Date until such certificate is delivered without a legend and (B) if the Company fails to (x) issue
and deliver (or cause to be delivered) to the Holder by the Legend Removal Date a certificate representing the New Securities so
delivered to the Company by the Holder that is free from all restrictive and other legends and (y) if after the Legend Removal
Date the Holder purchases (in an open market transaction or otherwise) shares of Common Stock to deliver in satisfaction of a sale
by the Holder of all or any portion of the number of shares of Common Stock, or a sale of a number of shares of Common Stock equal
to all or any portion of the number of shares of Common Stock, that the Holder anticipated receiving from the Company without any
restrictive legend, then an amount equal to the excess of the Holder’s total purchase price (including brokerage commissions
and other out-of-pocket expenses, if any) for the shares of Common Stock so purchased (including brokerage commissions and other
out-of-pocket expenses, if any) (the “Buy-In Price”) over the product of (I) such number of New Warrant Shares
that the Company was required to deliver to the Holder by the Legend Removal Date multiplied by (I) the lowest closing sale price
of the Common Stock on any Trading Day during the period commencing on the date of the delivery by the Holder to the Company of
the applicable New Warrant Shares (as the case may be) and ending on the date of such delivery and payment under this Section 4(a)(iv).

 

(v)       The
Cash Warrant Shares shall be issued free of legends.

 

(b)              
Disclosure of Transactions. The Company shall, within one business day of the Effective Date, issue a current report
on Form 8-K disclosing all material terms of the Transactions and including the form of this Agreement and the form of New Warrant
as exhibits thereto.

 

(c)               
Blue Sky. The Company shall make all filings and reports relating to the transactions contemplated hereby required
under applicable securities or “blue sky” laws of the states of the United States following the Closing Date, if any.

 

(d)              
Listing. The Company shall promptly secure the listing or designation for quotation (as applicable) of all of the
New Warrant Shares upon each trading market upon which the Common Stock is then listed or designated for quotation (as applicable)
(subject to official notice of issuance) and shall maintain such listing of all the New Warrant Shares from time to time issuable
under the terms of the New Warrants. The Company shall pay all fees and expenses in connection with satisfying its obligations
under this Section 4(d).

 

    	 	12	 

     

    

 

(e)               
Indemnification of Holder. Subject to the provisions of this Section 4(e), the Company will indemnify and hold the
Holder and its directors, officers, shareholders, members, managers, partners, employees and agents (and any other Persons with
a functionally equivalent role of a Person holding such titles notwithstanding a lack of such title or any other title), each Person
who controls the Holder (within the meaning of Section 15 of the Securities Act and Section 20 of the Exchange Act), and the directors,
officers, shareholders, agents, members, managers, partners or employees (and any other Persons with a functionally equivalent
role of a Person holding such titles notwithstanding a lack of such title or any other title) of such controlling persons (each,
a “Holder Party”) harmless from any and all losses, liabilities, obligations, claims, contingencies, damages,
costs and expenses, including all judgments, amounts paid in settlements, court costs and reasonable attorneys’ fees and
costs of investigation that any such Holder Party may suffer or incur as a result of or relating to (a) any breach of any of the
representations, warranties, covenants or agreements made by the Company in this Agreement, the other Transaction Documents, that
certain Warrant Amendment Agreement entered into on the date hereof between the Company and Holder (the “Warrant Amendment
Agreement”) or the Underwriting Agreement or (b) any claim or action instituted against the Holder Parties in any capacity,
or any of them or their respective Affiliates, by any stockholder of the Company or other third party who is not an Affiliate of
such Holder Party, with respect to the Transactions or any of the other transactions contemplated by the Transaction Documents,
the Warrant Amendment Agreement or the Underwriting Agreement. In addition to the foregoing but without duplication, the Company
hereby agrees to indemnify each Holder Party from and against, all economic loss and internal and out-of-pocket costs, including
without limitation: (i) loss of “benefit of the bargain”, (ii) diminution in the fully-diluted ownership percentage
of the Company, and (iii) counsel fees, that may be incurred by Holder Party or its Affiliates in connection with any assertion
that Koninklijke DSM N.V. or any of its affiliates (collectively, “DSM”) have not consented to the transactions
contemplated by the Transaction Documents (the “DSM Consent”). If any action shall be brought against any Holder
Party in respect of which indemnity may be sought pursuant to this Agreement, or if an event occurs for which a Holder Party is
entitled to indemnity in connection with failure to obtain the DSM Consent, such Holder Party shall promptly notify the Company
in writing, and in the event of an action being brought, the Company shall have the right to assume the defense thereof with counsel
of its own choosing reasonably acceptable to the Holder Party. Any Holder Party shall have the right to employ separate counsel
in any such action and participate in the defense thereof, but the fees and expenses of such counsel shall be at the expense of
such Holder Party except to the extent that (i) the employment thereof has been specifically authorized by the Company in writing,
(ii) the Company has failed after a reasonable period of time to assume such defense and to employ counsel or (iii) in such action
there is, in the reasonable opinion of counsel, a material conflict on any material issue between the position of the Company and
the position of such Holder Party, in which case the Company shall be responsible for the reasonable fees and expenses of no more
than one such separate counsel. The Company will not be liable to any Holder Party under this Agreement (y) for any settlement
by a Holder Party effected without the Company’s prior written consent, which shall not be unreasonably withheld or delayed;
or (z) to the extent, but only to the extent, that a loss, claim, damage or liability is attributable to such Holder’s breach
of any of the representations, warranties, covenants or agreements made by such Holder in this Agreement or in the other Transaction
Documents. The indemnification required by this Section 4(e) shall be made by periodic payments of the amount thereof during the
course of the investigation or defense, as and when bills are received or are incurred. The indemnity agreements contained herein
shall be in addition to any cause of action or similar right of any Holder Party against the Company or others and any liabilities
the Company may be subject to pursuant to law. Notwithstanding the foregoing, a Holder Party shall not be entitled to indemnification
hereunder to the extent it is determined in a binding adjudication that the matters to be indemnified are the direct and proximate
result of: (i) breach by such Holder Party of its representations, warranties or covenants under the Transaction Documents, (ii)
violation by such Holder Party of state or federal securities laws, or (iii) the result of the fraud, gross negligence or willful
misconduct of such Holder Party. Upon any such finding, such Holder Party shall promptly return to the Company all indemnification
payments that had previously been made hereunder with respect to matters for which it is not entitled to indemnity.

 

    	 	13	 

     

    

 

(f)               
Furnishing of Information. Until the earliest of the time that (i) the Holder owns no New Securities or (ii) the
New Warrants have expired, the Company covenants to use reasonable best efforts to timely file (or obtain extensions in respect
thereof and file within the applicable grace period) all reports required to be filed by the Company after the Closing Date pursuant
to the Exchange Act even if the Company is not then subject to the reporting requirements of the Exchange Act.

 

(g)              
Reservation of Common Stock. As of the Closing Date, the Company has reserved and the Company shall continue to reserve
and keep available at all times, free of preemptive or similar rights, a sufficient number of shares of Common Stock for the purpose
of enabling the Company to issue all of the New Warrant Shares issuable upon exercise of the New Warrants.

 

(h)              
Exercise Procedures. Each of the form of Notice of Exercise included in the New Warrants set forth the totality of
the procedures required of the Holder in order to exercise the New Warrants. Without limiting the preceding sentences, no ink-original
Notice of Exercise shall be required, nor shall any medallion guarantee (or other type of guarantee or notarization) of any Notice
of Exercise form be required in order to exercise the New Warrants. No additional legal opinion, other information or instructions
shall be required of the Holder to exercise its New Warrants. The Company shall honor exercises of the New Warrants and shall deliver
the New Warrant Shares in accordance with the terms, conditions and time periods set forth in the Transaction Documents.

 

 

 

    	 	14	 

     

    

 

(i)                
Credit Against Cash Warrant Exercise Price.   Each Holder shall credit against payment of the exercise price
of their respective Cash Warrants an aggregate amount of: (i) in the case of Vivo Capital Fund VIII, L.P. $107,771 of amounts owed
to such Holder by the Company; and (ii) in the case of Vivo Capital Surplus Fund VIII, L.P., $14,882 of amounts owed to such Holder
by the Company (collectively, the “Reimbursement Amounts”). The parties acknowledge the existence of such indebtedness
and agree that the Reimbursement Amounts will be applied to reduce the cash amount that each such Holder would otherwise deliver
to the Company for the “Initial Exercise” amount for such Holder, as indicated on their respective signature pages
to this Agreement.

 

5.                 
Miscellaneous.

 

(a)       Further
Assurances. Each party hereto shall promptly execute and deliver such further agreements and instruments, and take such further
actions, as the other party may reasonably request in order to carry out the purpose and intent of this Agreement.

 

(b)       Governing
Law; Jurisdiction; Jury Trial. This Agreement shall be governed by and construed and enforced in accordance with, and all questions
concerning the construction, validity, interpretation and performance of this Agreement shall be governed by, the internal laws
of the State of New York, without giving effect to any choice of law or conflict of law provision or rule (whether of the State
of New York or any other jurisdictions) that would cause the application of the laws of any jurisdictions other than the State
of New York. Each party hereby irrevocably waives personal service of process and consents to process being served in any such
suit, action or proceeding by mailing a copy thereof to the Company at the address for such notices to it under this Agreement
and agrees that such service shall constitute good and sufficient service of process and notice thereof. Each party hereby irrevocably
submits to the exclusive jurisdiction of the state and federal courts sitting in The City of New York, Borough of Manhattan, for
the adjudication of any dispute hereunder or in connection herewith or with any transaction contemplated hereby or discussed herein,
and hereby irrevocably waives, and agrees not to assert in any suit, action or proceeding, any claim that it is not personally
subject to the jurisdiction of any such court, that such suit, action or proceeding is brought in an inconvenient forum or that
the venue of such suit, action or proceeding is improper. Nothing contained herein shall be deemed to limit in any way any right
to serve process in any manner permitted by law. EACH PARTY HEREBY IRREVOCABLY WAIVES ANY RIGHT IT MAY HAVE TO, AND AGREES NOT
TO REQUEST, A JURY TRIAL FOR THE ADJUDICATION OF ANY DISPUTE HEREUNDER OR IN CONNECTION WITH OR ARISING OUT OF THIS AGREEMENT OR
ANY TRANSACTION CONTEMPLATED HEREBY.

 

(c)       Counterparts.
This Agreement may be executed in several counterparts, each of which shall be deemed an original, but all of which shall constitute
one and the same instrument.

 

(d)       Successors
and Assigns. Except as otherwise provided herein, the terms and conditions of this Agreement shall inure to the benefit of
and be binding upon the parties hereto and the respective successors and assigns of the parties. Nothing in this Agreement, express
or implied, is intended to confer upon any party, other than the parties hereto or their respective successors and assigns, any
rights, remedies, obligations or liabilities under or by reason of this Agreement, except as expressly provided in this Agreement.

 

    	 	15	 

     

    

 

(e)       Complete
Agreement. This Agreement, together with the Securities Purchase Agreement, the Underwriting Agreement, and the other Transaction
Documents (collectively, the “Exchange Documents”) represents the entire agreement and understandings between
the parties concerning the Transactions and the other matters described herein and therein and supersedes and replaces any and
all prior agreements and understandings solely with respect to the subject matter hereof and thereof. The parties acknowledge that
the Company and Holders have also entered into a Release Agreement dated August 17, 2018 that modifies the Exchange Documents in
some respects. Except as expressly set forth herein, nothing herein shall amend, modify or waive any term or condition of the other
Exchange Documents.

 

(f)       Expenses.
Except as specifically set forth herein, each party hereto shall bear its own costs and expenses, including, without limitation,
attorneys’ fees, incurred in connection with this Agreement and the transactions contemplated hereby.

 

(g)       Finder’s
Fees. Except as set forth in the Underwriting Agreement, each party represents that it neither is nor will be obligated for
any finder’s fee or commission in connection with this transaction. The Company shall indemnify and hold harmless the Holder
from any liability for any commission or compensation in the nature of a finder’s fee (and the reasonable costs and expenses
of defending against such liability or asserted liability) for which the Company or any of its officers, employees or representatives
is responsible.

 

(h)       Notices.
Any notices, consents, waivers or other communications required or permitted to be given under the terms of this Agreement must
be in writing and will be deemed to have been delivered: (i) upon receipt, when delivered personally; (ii) upon delivery, when
sent by facsimile (provided confirmation of transmission is mechanically or electronically generated and kept on file by the sending
party) or by electronic mail; or (iii) one Business Day after deposit with an overnight courier service, in each case properly
addressed to the party to receive the same. The addresses, facsimile numbers and e-mail addresses for such communications shall
be as set forth in the Securities Purchase Agreement or to such other address, facsimile number and/or e-mail address and/or to
the attention of such other Person as the recipient party has specified by written notice given to each other party five (5) days
prior to the effectiveness of such change. Written confirmation of receipt (A) given by the recipient of such notice, consent,
waiver or other communication, (B) mechanically or electronically generated by the sender’s facsimile machine or e-mail containing
the time, date, recipient facsimile number and an image of the first page of such transmission or (C) provided by an overnight
courier service shall be rebuttable evidence of personal service, receipt by facsimile or receipt from an overnight courier service
in accordance with clause (i), (ii) or (iii) above, respectively.

 

(i)       Amendments
and Waivers. Any term of this Agreement may be amended and the observance of any term of this Agreement may be waived (either
generally or in a particular instance and either retroactively or prospectively), only with the written consent of the Company
and the Holder.

 

    	 	16	 

     

    

 

(j)       Severability.
If one or more provisions of this Agreement are held to be unenforceable under applicable law, such provision shall be excluded
from this Agreement and the balance of the Agreement shall be interpreted as if such provision were so excluded and shall be enforceable
in accordance with its terms so long as this Agreement as so modified continues to express, without material change, the original
intentions of the parties as to the subject matter hereof and the prohibited nature, invalidity or unenforceability of the provision(s)
in question does not substantially impair the respective expectations or reciprocal obligations of the parties or the practical
realization of the benefits that would otherwise be conferred upon the parties. The parties will endeavor in good faith negotiations
to replace the prohibited, invalid or unenforceable provision(s) with a valid provision(s), the effect of which comes as close
as possible to that of the prohibited, invalid or unenforceable provision(s).

 

(k)       Interpretation.
Unless the context of this Agreement clearly requires otherwise, (i) references to the plural include the singular, the singular
the plural, the part the whole, (ii) references to any gender include all genders, (iii) “including” has the inclusive
meaning frequently identified with the phrase “but not limited to” and (iv) references to “hereunder” or
“herein” relate to this Agreement.

 

(l)       No
Third Party Beneficiaries. This Agreement is intended for the benefit of the parties hereto and their respective permitted
successors and assigns, and is not for the benefit of, nor may any provision hereof be enforced by, any other Person.

 

(m)       No
Strict Construction. The language used in this Agreement will be deemed to be the language chosen by the parties to express
their mutual intent, and no rules of strict construction will be applied against any party.

 

(n)       Independent
Nature of Holder’s Obligations and Rights. The obligations of the Holder under this Agreement are several and not joint
with the obligations of any Other Holder, and the Holder shall not be responsible in any way for the performance of the obligations
of any Other Holder under any Other Agreement. Nothing contained herein or in any Other Agreement, and no action taken by the Holder
pursuant hereto, shall be deemed to constitute the Holder and Other Holders as a partnership, an association, a joint venture or
any other kind of entity, or create a presumption that the Holder and Other Holders are in any way acting in concert or as a group
with respect to such obligations or the transactions contemplated by this Agreement or any Other Agreement and the Company acknowledges
that, to the best of its knowledge, the Holder and the Other Holders are not acting in concert or as a group with respect to such
obligations or the transactions contemplated by this Agreement or any Other Agreement. The Company and the Holder confirm that
the Holder has independently participated in the negotiation of the transactions contemplated hereby with the advice of its own
counsel and advisors. The Holder shall be entitled to independently protect and enforce its rights, including, without limitation,
the rights arising out of this Agreement, and it shall not be necessary for any Other Holder to be joined as an additional party
in any proceeding for such purpose

 

[signature page follows]

 

 

 

 

 

    	 	17	 

     

    

 

 

IN WITNESS WHEREOF, the
Holder and the Company have caused their respective signature page to this Agreement to be duly executed as of the date first written
above.

 

	 	AMYRIS, INC.
	 	 	 
	 	 	 
	 	By:	/s/ Kathleen Valiasek
	 	Name:  Kathleen Valiasek
	 	Title:  Chief Financial Officer

 

 

 

 

 

 

 

 

 

     

     

    

 

IN WITNESS WHEREOF, the
Holder and the Company have caused their respective signature page to this Agreement to be duly executed as of the date first written
above.

 

	 	HOLDER:
	 	 	 
	 	VIVO CAPITAL FUND VIII, L.P.
	 	 	 
	 	 	 
	 	By:	/s/ Frank Kung
	 	Name: Frank Kung
	 	Title: Managing Member of Vivo Capital VIII, LLC, General Partner
	 	 	 
	 	Address for delivery of New Warrants:
	 	 	 
	 	505 Hamilton Avenue, Suite 207, Palo Alto, CA 94301
	 	 	 
	 	 	 
	 	 	 
	 	 	 
	 	Aggregate Number of Cash Warrant Shares Issuable Upon Exercise of the Cash Warrant of the Holder*:
	 	 	 
	 	4,898,670
	 	 	 
	 	 	 
	 	 	 
	 	Aggregate Cash Warrant Share Exercise Amount*:
	 	 	 
	 	For Initial Exercise: 3,465,693
	 	For Second Exercise: Up to 1,432,977
	 	 	 
	 	Aggregate Exercise Price of Cash Warrant Share Exercise Amount
	 	 	 
	 	For Initial Exercise: $15,249,049.20
	 	 	 
	 	For Second Exercise: Up to $6,305,098.80
	 	*Disregarding any limitations on exercise related thereto.
	 	 	 
	 	 	 
	 	_______Check here if Holder is electing to have the 180 day lock-up provisions in Annex I attached hereto apply to Holder’s Cash Warrant Share Exercise Amount of Cash Warrant Shares to permit a cashless exercise of the Cash Warrant

 

 

 

 

     

     

    

 

Annex I

 

Required Lock-Up Provisions for Cashless Exercise of Cash Warrant

 

In consideration of the Company granting the
Holder the right to cashless exercise, in whole or in part, the Cash Warrant (in lieu of the required cash exercise pursuant to
the Notice of Exercise) and still participate in the other Transactions and for other good and valuable consideration, receipt
of which is hereby acknowledged, the Holder will not, during the period beginning on the date hereof and continuing to and including
the date 180 days after the date hereof, (1) offer, pledge, announce the intention to sell, sell, contract to sell, sell any option
or contract to purchase, purchase any option or contract to sell, grant any option, right or warrant to purchase, or otherwise
transfer or dispose of, directly or indirectly, any Cash Warrant Shares, or (2) enter into any swap or other agreement that transfers,
in whole or in part, any of the economic consequences of ownership of any Cash Warrant Shares, whether any such transaction described
in clause (1) or (2) above is to be settled by delivery of any Cash Warrant Shares, in cash or otherwise. The foregoing restrictions
are expressly agreed to preclude the Holder from engaging in any hedging or other transaction which is designed to or reasonably
expected to lead to or result in a sale or disposition of any Cash Warrant Shares even if such securities would be disposed of
by someone other than the Holder.

 

Notwithstanding the foregoing, the restrictions
set forth in clause (1) and (2) above shall not apply to transfers (a) as a bona fide gift or gifts, provided that the donee or
donees thereof agree to be bound in writing by the restrictions set forth herein or (b) to any trust for the direct or indirect
benefit of the Holder or the immediate family of the Holder, provided that the trustee of the trust agrees to be bound in writing
by the restrictions set forth herein, and provided further that any such transfer shall not involve a disposition for value. For
purposes of this Annex I, “immediate family” shall mean any relationship by blood, marriage or adoption, not
more remote than first cousin.

 

 

 

     

     

    

 

Exhibit A

 

 

 

 

 

 

 

 

 

 

 

 

     

     

    

 

NEITHER THIS SECURITY NOR THE SECURITIES INTO WHICH THIS SECURITY
IS EXERCISABLE HAS BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE
UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY,
MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR PURSUANT TO AN AVAILABLE
EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT AND IN ACCORDANCE WITH
APPLICABLE STATE SECURITIES LAWS. THIS SECURITY AND THE SECURITIES ISSUABLE UPON EXERCISE OF THIS SECURITY MAY BE PLEDGED IN CONNECTION
WITH A BONA FIDE MARGIN ACCOUNT WITH A REGISTERED BROKER-DEALER OR OTHER LOAN WITH A FINANCIAL INSTITUTION THAT IS AN “ACCREDITED
INVESTOR” AS DEFINED IN RULE 501(a) UNDER THE SECURITIES ACT OR OTHER LOAN SECURED BY SUCH SECURITIES.

 

COMMON STOCK PURCHASE WARRANT

 

AMYRIS, INC. 

 

Warrant Shares: _______________1Issue Date: August [_], 2018

 

THIS COMMON STOCK PURCHASE WARRANT (the “Warrant”)
certifies that, for value received, Vivo Fund VIII, L.P. or its assigns (the “Holder”) is entitled, upon the
terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the open of
business on the six month anniversary of the date hereof (the “Initial Exercise Date”) and on or prior to the
close of business on the fifteen month anniversary of the Initial Exercise Date (the “Termination Date”) but
not thereafter, to subscribe for and purchase from Amyris, Inc., a Delaware corporation (the “Company”), up
to _________ shares (as subject to adjustment hereunder, the “Warrant Shares”) of Common Stock. The purchase
price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b).

 

Section 1.Definitions.
Capitalized terms used and not otherwise defined herein shall have the meanings set forth in that certain Warrant Exercise Agreement
(the “Warrant Exercise Agreement”), dated August 17, 2018, among the Company and the Holder, as such definitions
are in effect on August 17, 2018.

 

Section 2.Exercise.

 

a)                 
Exercise of Warrant. Exercise of the purchase rights represented by this Warrant may be made, in whole or in part,
at any time or times on or after the Initial Exercise Date and on or before the Termination Date by delivery to the Company of
a duly executed facsimile copy or PDF copy submitted by electronic (or e-mail attachment) of the Notice of Exercise in the form
annexed hereto (“Notice of Exercise”). Within two (2) Trading Days following the date of exercise as aforesaid,
the Holder shall deliver the aggregate Exercise Price for the shares specified in the applicable Notice of Exercise by wire transfer
or cashier’s check drawn on a United States bank unless the cashless exercise procedure specified in Section 2(c) below is
specified in the applicable Notice of Exercise. No ink-original Notice of Exercise shall be required, nor shall any medallion guarantee
(or other type of guarantee or notarization) of any Notice of Exercise form be required. Notwithstanding anything herein to the
contrary, the Holder shall not be required to physically surrender this Warrant to the Company until the Holder has purchased all
of the Warrant Shares available hereunder and the Warrant has been exercised in full, in which case, the Holder shall surrender
this Warrant to the Company for cancellation within three (3) Trading Days of the date the final Notice of Exercise is delivered
to the Company. Partial exercises of this Warrant resulting in purchases of a portion of the total number of Warrant Shares available
hereunder shall have the effect of lowering the outstanding number of Warrant Shares purchasable hereunder in an amount equal to
the applicable number of Warrant Shares purchased. The Company shall maintain records showing the number of Warrant Shares purchased
and the date of such purchases. The Company shall deliver any objection to any Notice of Exercise within one (1) Business Day of
receipt of such notice. The Holder and any assignee, by acceptance of this Warrant, acknowledge and agree that, by reason of
the provisions of this paragraph, following the purchase of a portion of the Warrant Shares hereunder, the number of Warrant Shares
available for purchase hereunder at any given time may be less than the amount stated on the face hereof.

 

 

________________

1
The New Warrant issued on the Initial Exercise Date will be for 4,488,072 shares. The New Warrant issued on the Second Exercise
Date will be for up to 1,855,706 shares.

    	 	1	 

     

    

 

b)                 
Exercise Price. The exercise price per share of the Common Stock under this Warrant shall be $7.52, subject to adjustment
hereunder (the “Exercise Price”).

 

c)                 
Cashless Exercise. Notwithstanding anything contained herein to the contrary, if a registration statement covering
the resale of the Warrant Shares subject to the applicable Notice of Exercise is not available for the resale of such Warrant Shares,
at any time after the six month anniversary of the Initial Exercise Date, this Warrant may be exercised, in whole or in part, at
any time or times on or after the Initial Exercise Date and on or before the Termination Date at the election of the Holder (in
such Holder’s sole discretion) by means of a “cashless exercise” in which the Holder shall be entitled to receive
a number of Warrant Shares equal to the quotient obtained by dividing ((A-B) * (X)) by (A), where:

 

(A) = as applicable: (i) the VWAP on
the Trading Day immediately preceding the date of the applicable Notice of Exercise if such Notice of Exercise is (1) both executed
and delivered pursuant to Section 2(a) hereof on a day that is not a Trading Day or (2) both executed and delivered pursuant to
Section 2(a) hereof on a Trading Day prior to the opening of “regular trading hours” (as defined in Rule 600(b)(64)
of Regulation NMS promulgated under the federal securities laws) on such Trading Day, (ii) at the option of the Holder, either
(y) the VWAP on the Trading Day immediately preceding the date of the applicable Notice of Exercise or (z) the Bid Price of the
Common Stock on the principal Trading Market as reported by Bloomberg L.P. as of the time of the Holder’s execution of the
applicable Notice of Exercise if such Notice of Exercise is executed during “regular trading hours” on a Trading Day
and is delivered within two (2) hours thereafter (including until two (2) hours after the close of “regular trading hours”
on a Trading Day) pursuant to Section 2(a) hereof or (iii) the VWAP on the date of the applicable Notice of Exercise if the date
of such Notice of Exercise is a Trading Day and such Notice of Exercise is both executed and delivered pursuant to Section 2(a)
hereof after the close of “regular trading hours” on such Trading Day;

 

(B) = the Exercise Price of this
Warrant, as adjusted hereunder; and

 

(X) = the number of Warrant Shares
that would be issuable upon exercise of this Warrant in accordance with the terms of this Warrant if such exercise were by means
of a cash exercise rather than a cashless exercise.

 

    	 	2	 

     

    

 

If
Warrant Shares are issued in such a cashless exercise, the parties acknowledge and agree that in accordance with Section 3(a)(9)
of the Securities Act, the Warrant Shares shall take on the characteristics of the Warrants being exercised, and the holding period
of the Warrant Shares being issued may be tacked on to the holding period of this Warrant.  The Company agrees not to
take any position contrary to this Section 2(c).

 

“Bid Price” means,
for any date, the price determined by the first of the following clauses that applies: (a) if the Common Stock is then listed or
quoted on a Trading Market, the bid price of the Common Stock for the time in question (or the nearest preceding date) on the Trading
Market on which the Common Stock is then listed or quoted as reported by Bloomberg L.P. (based on a Trading Day from 9:30 a.m.
(New York City time) to 4:02 p.m. (New York City time)), (b)  if OTCQB or OTCQX is not a Trading Market, the volume weighted
average price of the Common Stock for such date (or the nearest preceding date) on OTCQB or OTCQX as applicable, (c) if the Common
Stock is not then listed or quoted for trading on OTCQB or OTCQX and if prices for the Common Stock are then reported in the “Pink
Sheets” published by OTC Markets Group, Inc. (or a similar organization or agency succeeding to its functions of reporting
prices), the most recent bid price per share of the Common Stock so reported, or (d) in all other cases, the fair market value
of a share of Common Stock as determined by an independent appraiser selected in good faith by the Holder and reasonably acceptable
to the Company, the fees and expenses of which shall be paid by the Company.

 

“VWAP” means, for
any date, the price determined by the first of the following clauses that applies: (a) if the Common Stock is then listed or quoted
on a Trading Market, the daily volume weighted average price of the Common Stock for such date (or the nearest preceding date)
on the Trading Market on which the Common Stock is then listed or quoted as reported by Bloomberg L.P. (based on a Trading Day
from 9:30 a.m. (New York City time) to 4:02 p.m. (New York City time)), (b)  if OTCQB or OTCQX is not a Trading Market, the
volume weighted average price of the Common Stock for such date (or the nearest preceding date) on OTCQB or OTCQX as applicable,
(c) if the Common Stock is not then listed or quoted for trading on OTCQB or OTCQX and if prices for the Common Stock are then
reported in the “Pink Sheets” published by OTC Markets Group, Inc. (or a similar organization or agency succeeding
to its functions of reporting prices), the most recent bid price per share of the Common Stock so reported, or (d) in all
other cases, the fair market value of a share of Common Stock as determined by an independent appraiser selected in good faith
by the Holder and reasonably acceptable to the Company, the fees and expenses of which shall be paid by the Company.

 

    	 	3	 

     

    

 

Notwithstanding anything herein to
the contrary, on the Termination Date, if a registration statement covering the resale of the Warrant Shares is not available for
the resale of the Warrant Shares, this Warrant shall be automatically exercised via cashless exercise pursuant to this Section
2(c).

 

d)       
Mechanics of Exercise.

 

 i. Delivery of Warrant Shares Upon Exercise. Warrant Shares purchased hereunder shall be transmitted by the Transfer Agent to the Holder by crediting the account of the Holder’s or its designee’s balance account with The Depository Trust Company through its Deposit or Withdrawal at Custodian system (“DWAC”) if the Company is then a participant in such system and either (A) there is an effective registration statement permitting the issuance of the Warrant Shares to or resale of the Warrant Shares by the Holder or (B) the Warrant Shares are eligible for resale by the Holder without volume or manner-of-sale limitations pursuant to Rule 144, and otherwise by physical delivery of a certificate, registered in the Company’s share register in the name of the Holder or its designee, for the number of Warrant Shares to which the Holder is entitled pursuant to such exercise to the address specified by the Holder in the Notice of Exercise by the date that is the earlier of (i) two (2) Trading Days after the delivery to the Company of the Notice of Exercise and (ii) one (1) Trading Day after delivery of the aggregate Exercise Price to the Company (such date, the “Warrant Share Delivery Date”). Upon delivery of the Notice of Exercise, the Holder shall be deemed for all corporate purposes to have become the holder of record of the Warrant Shares with respect to which this Warrant has been exercised, irrespective of the date of delivery of the Warrant Shares, provided that payment of the aggregate Exercise Price (other than in the case of a cashless exercise) is received within two (2) Trading following delivery of the Notice of Exercise. If the Company fails for any reason to deliver to the Holder the Warrant Shares subject to a Notice of Exercise by the Warrant Share Delivery Date, the Company shall pay to the Holder, in cash, as liquidated damages and not as a penalty, for each $1,000 of Warrant Shares subject to such exercise (based on the VWAP of the Common Stock on the date of the applicable Notice of Exercise), $10 per Trading Day (increasing to $20 per Trading Day on the fifth Trading Day after such liquidated damages begin to accrue) for each Trading Day commencing one Trading Day after such Warrant Share Delivery Date until such Warrant Shares are delivered or Holder rescinds such exercise. The Company agrees to maintain a transfer agent that is a participant in the FAST program so long as this Warrant remains outstanding and exercisable.

 

    	 	4	 

     

    

 

ii.                     Delivery
of New Warrants Upon Exercise. If this Warrant shall have been exercised in part, the Company shall, at the request of a Holder
and upon surrender of this Warrant certificate, at the time of delivery of the Warrant Shares, deliver to the Holder a new Warrant
evidencing the rights of the Holder to purchase the unpurchased Warrant Shares called for by this Warrant, which new Warrant shall
in all other respects be identical with this Warrant.

 

iii.                  Rescission
Rights. If the Company fails to cause the Transfer Agent to transmit to the Holder the Warrant Shares pursuant to Section 2(d)(i)
by the Warrant Share Delivery Date, then the Holder will have the right to rescind such exercise.

 

iv.                  Compensation
for Buy-In on Failure to Timely Deliver Warrant Shares Upon Exercise. In addition to any other rights available to the Holder,
if the Company fails to cause the Transfer Agent to transmit to the Holder the Warrant Shares in accordance with the provisions
of Section 2(d)(i) above pursuant to an exercise on or before the Warrant Share Delivery Date, and if after such date the Holder
is required by its broker to purchase (in an open market transaction or otherwise) or the Holder’s brokerage firm otherwise
purchases, shares of Common Stock to deliver in satisfaction of a sale by the Holder of the Warrant Shares which the Holder anticipated
receiving upon such exercise (a “Buy-In”), then the Company shall (A) pay in cash to the Holder the amount,
if any, by which (x) the Holder’s total purchase price (including brokerage commissions, if any) for the shares of Common
Stock so purchased exceeds (y) the amount obtained by multiplying (1) the number of Warrant Shares that the Company was required
to deliver to the Holder in connection with the exercise at issue times (2) the price at which the sell order giving rise to such
purchase obligation was executed, and (B) at the option of the Holder, either reinstate the portion of the Warrant and equivalent
number of Warrant Shares for which such exercise was not honored (in which case such exercise shall be deemed rescinded) or deliver
to the Holder the number of shares of Common Stock that would have been issued had the Company timely complied with its exercise
and delivery obligations hereunder. For example, if the Holder purchases Common Stock having a total purchase price of $11,000
to cover a Buy-In with respect to an attempted exercise of shares of Common Stock with an aggregate sale price giving rise to such
purchase obligation of $10,000, under clause (A) of the immediately preceding sentence the Company shall be required to pay the
Holder $1,000. The Holder shall provide the Company written notice indicating the amounts payable to the Holder in respect of the
Buy-In and, upon request of the Company, evidence of the amount of such loss. Nothing herein shall limit a Holder’s right
to pursue any other remedies available to it hereunder, at law or in equity including, without limitation, a decree of specific
performance and/or injunctive relief with respect to the Company’s failure to timely deliver shares of Common Stock upon
exercise of the Warrant as required pursuant to the terms hereof.

 

    	 	5	 

     

    

 

v.                  No Fractional
Shares or Scrip. No fractional shares or scrip representing fractional shares shall be issued upon the exercise of this Warrant.
As to any fraction of a share which the Holder would otherwise be entitled to purchase upon such exercise, the Company shall, at
its election, either pay a cash adjustment in respect of such final fraction in an amount equal to such fraction multiplied by
the Exercise Price or round up to the next whole share.

 

vi.                  Charges, Taxes
and Expenses. Issuance of Warrant Shares shall be made without charge to the Holder for any issue or transfer tax or other
incidental expense in respect of the issuance of such Warrant Shares, all of which taxes and expenses shall be paid by the Company,
and such Warrant Shares shall be issued in the name of the Holder or in such name or names as may be directed by the Holder; provided,
however, that in the event that Warrant Shares are to be issued in a name other than the name of the Holder, this Warrant
when surrendered for exercise shall be accompanied by the Assignment Form attached hereto duly executed by the Holder and the Company
may require, as a condition thereto, the payment of a sum sufficient to reimburse it for any transfer tax incidental thereto. The
Company shall pay all Transfer Agent fees required for same-day processing of any Notice of Exercise and all fees to the Depository
Trust Company (or another established clearing corporation performing similar functions) required for same-day electronic delivery
of the Warrant Shares.

 

vii.                  Closing of
Books. The Company will not close its stockholder books or records in any manner which prevents the timely exercise of this
Warrant, pursuant to the terms hereof.

 

    	 	6	 

     

    

 

e)        
Holder’s Exercise Limitations. Notwithstanding anything to the contrary contained herein, the Company shall
not effect any exercise of this Warrant, and a Holder shall not have the right to exercise any portion of this Warrant, pursuant
to Section 2 or otherwise, to the extent that after giving effect to such issuance after exercise as set forth on the applicable
Notice of Exercise, the Holder (together with the Holder’s Affiliates, and any other Persons acting as a group together with
the Holder or any of the Holder’s Affiliates (such Persons, “Attribution Parties”)), would beneficially
own in excess of the Beneficial Ownership Limitation (as defined below).  For purposes of the foregoing sentence, the number
of shares of Common Stock beneficially owned by the Holder and its Affiliates and Attribution Parties shall include the number
of shares of Common Stock issuable upon exercise of this Warrant with respect to which such determination is being made, but shall
exclude the number of shares of Common Stock which would be issuable upon (i) exercise of the remaining, nonexercised portion of
this Warrant beneficially owned by the Holder or any of its Affiliates or Attribution Parties and (ii) exercise or conversion of
the unexercised or nonconverted portion of any other securities of the Company (including, without limitation, any other Common
Stock Equivalents (as defined below)) subject to a limitation on conversion or exercise analogous to the limitation contained herein
beneficially owned by the Holder or any of its Affiliates or Attribution Parties.  Except as set forth in the preceding sentence,
for purposes of this Section 2(e), beneficial ownership shall be calculated in accordance with Section 13(d) of the Exchange Act
and the rules and regulations promulgated thereunder, it being acknowledged by the Holder that the Company is not representing
to the Holder that such calculation is in compliance with Section 13(d) of the Exchange Act and the Holder is solely responsible
for any schedules required to be filed in accordance therewith. To the extent that the limitation contained in this Section 2(e)
applies, the determination of whether this Warrant is exercisable (in relation to other securities owned by the Holder together
with any Affiliates and Attribution Parties) and of which portion of this Warrant is exercisable shall be in the sole discretion
of the Holder, and the submission of a Notice of Exercise shall be deemed to be the Holder’s determination of whether this
Warrant is exercisable (in relation to other securities owned by the Holder together with any Affiliates and Attribution Parties)
and of which portion of this Warrant is exercisable, in each case subject to the Beneficial Ownership Limitation, and the Company
shall have no obligation to verify or confirm the accuracy of such determination. In addition, a determination as to any group
status as contemplated above shall be determined in accordance with Section 13(d) of the Exchange Act and the rules and regulations
promulgated thereunder. For purposes of this Section 2(e), in determining the number of outstanding shares of Common Stock, a Holder
may rely on the number of outstanding shares of Common Stock as reflected in (A) the Company’s most recent periodic or annual
report filed with the Commission, as the case may be, (B) a more recent public announcement by the Company or (C) a more recent
written notice by the Company or the Transfer Agent setting forth the number of shares of Common Stock outstanding.  Upon
the written or oral request of a Holder, the Company shall within two Trading Days confirm orally and in writing to the Holder
the number of shares of Common Stock then outstanding.  In any case, the number of outstanding shares of Common Stock shall
be determined after giving effect to the conversion or exercise of securities of the Company, including this Warrant, by the Holder
or its Affiliates or Attribution Parties since the date as of which such number of outstanding shares of Common Stock was reported.
The “Beneficial Ownership Limitation” shall be 9.99% of the number of shares of the Common Stock outstanding
immediately after giving effect to the issuance of shares of Common Stock issuable upon exercise of this Warrant. The Holder, upon
notice to the Company, may waive the Beneficial Ownership Limitation provisions of this Section 2(e), provided that such waiver
(i) will not be effective until the 61st day after such notice is delivered to the Company, and (ii) will not be
effective to the extent such waiver would require the prior approval of the Company’s stockholders, unless such approval
has been obtained. If such stockholder approval is required and has not been obtained, the Company shall use its commercially reasonable
efforts to timely obtain such stockholder approval. The provisions of this paragraph shall be construed and implemented in a manner
otherwise than in strict conformity with the terms of this Section 2(e) to correct this paragraph (or any portion hereof) which
may be defective or inconsistent with the intended Beneficial Ownership Limitation herein contained or to make changes or supplements
necessary or desirable to properly give effect to such limitation. The limitations contained in this paragraph shall apply to a
successor holder of this Warrant. “Common Stock Equivalents” means any securities of the Company or its subsidiaries
which would entitle the holder thereof to acquire at any time Common Stock, including, without limitation, any debt, preferred
stock, right, option, warrant or other instrument that is at any time convertible into, or exercisable or exchangeable for, or
otherwise entitles the holder thereof to receive, Common Stock.

 

    	 	7	 

     

    

 

Section 3.Certain
Adjustments.

 

a)     
Stock Dividends and Splits. If the Company, at any time while this Warrant is outstanding: (i) pays a stock dividend
or otherwise makes a distribution or distributions on shares of its Common Stock or any other equity or equity equivalent securities
payable in shares of Common Stock (which, for avoidance of doubt, shall not include any shares of Common Stock issued by the Company
upon exercise of this Warrant), (ii) subdivides outstanding shares of Common Stock into a larger number of shares, (iii) combines
(including by way of reverse stock split) outstanding shares of Common Stock into a smaller number of shares or (iv) issues by
reclassification of shares of the Common Stock any shares of capital stock of the Company, then in each case the Exercise Price
shall be multiplied by a fraction of which the numerator shall be the number of shares of Common Stock (excluding treasury shares,
if any) outstanding immediately before such event and of which the denominator shall be the number of shares of Common Stock outstanding
immediately after such event, and the number of shares issuable upon exercise of this Warrant shall be proportionately adjusted
such that the aggregate Exercise Price of this Warrant shall remain unchanged. Any adjustment made pursuant to this Section 3(a)
shall become effective immediately after the record date for the determination of stockholders entitled to receive such dividend
or distribution and shall become effective immediately after the effective date in the case of a subdivision, combination or re-classification.

 

b)     
[INTENTIONALLY OMITTED]

 

 c)     Subsequent Rights Offerings. In addition to any adjustments pursuant to Section 3(a) above, if at any time after the Original Issue Date the Company grants, issues or sells any Common Stock Equivalents or rights to purchase stock, warrants, securities or other property pro rata to the record holders of any class of shares of Common Stock (the “Purchase Rights”), then each Holder will be entitled to acquire, upon the terms applicable to such Purchase Rights, the aggregate Purchase Rights which the Holder could have acquired if the Holder had held the number of shares of Common Stock acquirable upon complete exercise of this Warrant (without regard to any limitations on exercise hereof, including without limitation, the Beneficial Ownership Limitation) immediately before the date on which a record is taken for the grant, issuance or sale of such Purchase Rights, or, if no such record is taken, the date as of which the record holders of shares of Common Stock are to be determined for the grant, issue or sale of such Purchase Rights (provided, however, to the extent that the Holder’s right to participate in any such Purchase Right would result in the Holder exceeding the Beneficial Ownership Limitation and the Beneficial Ownership Limitation is not waived by the Holder, then the Holder shall not be entitled to participate in such Purchase Right to such extent (or beneficial ownership of such shares of Common Stock as a result of such Purchase Right to such extent) and such Purchase Right to such extent shall be held in abeyance for the Holder until such time, if ever, as its right thereto would not result in the Holder exceeding the Beneficial Ownership Limitation).

 

    	 	8	 

     

    

 

d)    
Pro Rata Distributions. During such time as this Warrant is outstanding, if the Company shall declare or make any
dividend or other distribution of its assets (or rights to acquire its assets) to holders of shares of Common Stock, by way of
return of capital or otherwise (including, without limitation, any distribution of cash, stock or other securities, property or
options by way of a dividend, spin off, reclassification, corporate rearrangement, scheme of arrangement or other similar transaction,
but excluding any dividend that results in adjustment to the Conversion Price pursuant to Section 3(a) above) (a “Distribution”),
at any time after the issuance of this Warrant, then, in each such case, the Holder shall be entitled to participate in such Distribution
to the same extent that the Holder would have participated therein if the Holder had held the number of shares of Common Stock
acquirable upon complete exercise of this Warrant (without regard to any limitations on exercise hereof, including without limitation,
the Beneficial Ownership Limitation) immediately before the date of which a record is taken for such Distribution, or, if no such
record is taken, the date as of which the record holders of shares of Common Stock are to be determined for the participation in
such Distribution (provided, however, to the extent that the Holder's right to participate in any such Distribution
would result in the Holder exceeding the Beneficial Ownership Limitation and the Beneficial Ownership Limitation is not waived
by the Holder, then the Holder shall not be entitled to participate in such Distribution to such extent (or in the beneficial ownership
of any shares of Common Stock as a result of such Distribution to such extent) and the portion of such Distribution shall be held
in abeyance for the benefit of the Holder until such time, if ever, as its right thereto would not result in the Holder exceeding
the Beneficial Ownership Limitation).

 

e)     
Fundamental Transaction. If, at any time while this Warrant is outstanding, (i) the Company, directly or indirectly,
in one or more related transactions effects any merger or consolidation of the Company with or into another Person, (ii) the Company,
directly or indirectly, effects any sale, lease, license, assignment, transfer, conveyance or other disposition of all or substantially
all of its assets in one or a series of related transactions, (iii) any, direct or indirect, purchase offer, tender offer or exchange
offer (whether by the Company or another Person) is completed pursuant to which holders of Common Stock are permitted to sell,
tender or exchange their shares for other securities, cash or property and has been accepted by the holders of 50% or more of the
outstanding Common Stock, (iv) the Company, directly or indirectly, in one or more related transactions effects any reclassification,
reorganization or recapitalization of the Common Stock or any compulsory share exchange pursuant to which the Common Stock is effectively
converted into or exchanged for other securities, cash or property, or (v) the Company, directly or indirectly, in one or more
related transactions consummates a stock or share purchase agreement or other business combination (including, without limitation,
a reorganization, recapitalization, spin-off or scheme of arrangement) with another Person or group of Persons whereby such other
Person or group acquires more than 50% of the outstanding shares of Common Stock (not including any shares of Common Stock held
by the other Person or other Persons making or party to, or associated or affiliated with the other Persons making or party to,
such stock or share purchase agreement or other business combination) (each a “Fundamental Transaction”), then,
the Holder shall have the right to receive, for each Warrant Share that would have been issuable upon such exercise immediately
prior to the occurrence of such Fundamental Transaction (as if the exercise of the Warrant occurred immediately prior to the occurrence
of such Fundamental Transaction), at the option of the Holder (without regard to any limitation in Section 2(e) on the exercise
of this Warrant), the number of shares of common stock of the successor or acquiring corporation or shares of Common Stock of the
Company, if it is the surviving corporation, and any additional consideration (the “Alternate Consideration”)
receivable as a result of such Fundamental Transaction by a holder of the number of shares of Common Stock for which this Warrant
is exercisable immediately prior to such Fundamental Transaction (without regard to any limitation in Section 2(e) on the exercise
of this Warrant). For purposes of any such exercise, the determination of the Exercise Price shall be appropriately adjusted to
apply to such Alternate Consideration based on the amount of Alternate Consideration issuable in respect of one share of Common
Stock in such Fundamental Transaction, and the Company shall apportion the Exercise Price among the Alternate Consideration in
a reasonable manner reflecting the relative value of any different components of the Alternate Consideration. If holders of Common
Stock are given any choice as to the securities, cash or property to be received in a Fundamental Transaction, then the Holder
shall be given the same choice as to the Alternate Consideration it receives upon any exercise of this Warrant following such Fundamental
Transaction.

 

    	 	9	 

     

    

 

f)      
Calculations. All calculations under this Section 3 shall be made to the nearest cent or the nearest 1/100th of a
share, as the case may be. For purposes of this Section 3, the number of shares of Common Stock deemed to be issued and outstanding
as of a given date shall be the sum of the number of shares of Common Stock (excluding treasury shares, if any) issued and outstanding.

 

g)     
Notice to Holder.

 

i.      Adjustment to Exercise Price. Whenever the Exercise Price is adjusted pursuant to
any provision of this Section 3, the Company shall within two (2) Trading Days deliver to the Holder by facsimile or email a notice
setting forth the Exercise Price after such adjustment and any resulting adjustment to the number of Warrant Shares and setting
forth a brief statement of the facts requiring such adjustment.

 

    	 	10	 

     

    

 

ii.      Notice to Allow Exercise by Holder. If (A) the Company shall declare a dividend
(or any other distribution in whatever form) on the Common Stock, (B) the Company shall declare a special nonrecurring cash dividend
on or a redemption of the Common Stock, (C) the Company shall authorize the granting to all holders of the Common Stock rights
or warrants to subscribe for or purchase any shares of capital stock of any class or of any rights, (D) the approval of any stockholders
of the Company shall be required in connection with any reclassification of the Common Stock, any consolidation or merger to which
the Company is a party, any sale or transfer of all or substantially all of the assets of the Company, or any compulsory share
exchange whereby the Common Stock is converted into other securities, cash or property, or (E) the Company shall authorize the
voluntary or involuntary dissolution, liquidation or winding up of the affairs of the Company, then, in each case, the Company
shall cause to be delivered by facsimile or email to the Holder at its last facsimile number or email address as it shall appear
upon the Warrant Register of the Company, at least 20 calendar days prior to the applicable record or effective date hereinafter
specified, a notice stating (x) the date on which a record is to be taken for the purpose of such dividend, distribution, redemption,
rights or warrants, or if a record is not to be taken, the date as of which the holders of the Common Stock of record to be entitled
to such dividend, distributions, redemption, rights or warrants are to be determined or (y) the date on which such reclassification,
consolidation, merger, sale, transfer or share exchange is expected to become effective or close, and the date as of which it is
expected that holders of the Common Stock of record shall be entitled to exchange their shares of the Common Stock for securities,
cash or other property deliverable upon such reclassification, consolidation, merger, sale, transfer or share exchange; provided
that the failure to deliver such notice or any defect therein or in the delivery thereof shall not affect the validity of the corporate
action required to be specified in such notice. To the extent that any notice provided in this Warrant constitutes, or contains,
material, non-public information regarding the Company or any of the Subsidiaries, the Company shall simultaneously file such notice
with the Commission pursuant to a Current Report on Form 8-K. The Holder shall remain entitled to exercise this Warrant during
the period commencing on the date of such notice to the effective date of the event triggering such notice except as may otherwise
be expressly set forth herein.

 

Section 4.Transfer
of Warrant.

 

a)     
Transferability. Subject to compliance with any applicable securities laws and the conditions set forth in Section
4(d) hereof and to the provisions of Section 4(a) of the Warrant Exercise Agreement, this Warrant and all rights hereunder are
transferable, in whole or in part, upon surrender of this Warrant at the principal office of the Company or its designated agent,
together with a written assignment of this Warrant substantially in the form attached hereto duly executed by the Holder or its
agent or attorney and funds sufficient to pay any transfer taxes payable upon the making of such transfer. Upon such surrender
and, if required, such payment, the Company shall execute and deliver a new Warrant or Warrants in the name of the assignee or
assignees, as applicable, and in the denomination or denominations specified in such instrument of assignment, and shall issue
to the assignor a new Warrant evidencing the portion of this Warrant not so assigned, and this Warrant shall promptly be cancelled.
Notwithstanding anything herein to the contrary, the Holder shall not be required to physically surrender this Warrant to the Company
unless the Holder has assigned this Warrant in full, in which case, the Holder shall surrender this Warrant to the Company within
three (3) Trading Days of the date the Holder delivers an assignment form to the Company assigning this Warrant full. The Warrant,
if properly assigned in accordance herewith, may be exercised by a new holder for the purchase of Warrant Shares without having
a new Warrant issued.

 

    	 	11	 

     

    

 

b)     
New Warrants. This Warrant may be divided or combined with other Warrants upon presentation hereof at the aforesaid
office of the Company, together with a written notice specifying the names and denominations in which new Warrants are to be issued,
signed by the Holder or its agent or attorney. Subject to compliance with Section 4(a), as to any transfer which may be involved
in such division or combination, the Company shall execute and deliver a new Warrant or Warrants in exchange for the Warrant or
Warrants to be divided or combined in accordance with such notice. All Warrants issued on transfers or exchanges shall be dated
the original issue date and shall be identical with this Warrant except as to the number of Warrant Shares issuable pursuant thereto.

 

c)     
Warrant Register. The Company shall register this Warrant, upon records to be maintained by the Company for that
purpose (the “Warrant Register”), in the name of the record Holder hereof from time to time. The Company may
deem and treat the registered Holder of this Warrant as the absolute owner hereof for the purpose of any exercise hereof or any
distribution to the Holder, and for all other purposes, absent actual notice to the contrary.

 

d)    
Transfer Restrictions. If, at the time of the surrender of this Warrant in connection with any transfer of this Warrant,
the transfer of this Warrant shall not be either (i) registered pursuant to an effective registration statement under the Securities
Act and under applicable state securities or blue sky laws or (ii) eligible for resale without volume or manner-of-sale restrictions
or current public information requirements pursuant to Rule 144, the Company may require, as a condition of allowing such transfer,
that the Holder or transferee of this Warrant, as the case may be, comply with the provisions of Section 4(a) of the Warrant Exercise
Agreement.

 

e)     
Representation by the Holder. The Holder, by the acceptance hereof, represents and warrants that it is acquiring
this Warrant and, upon any exercise hereof, will acquire the Warrant Shares issuable upon such exercise, for its own account and
not with a view to or for distributing or reselling such Warrant Shares or any part thereof in violation of the Securities Act
or any applicable state securities law, except pursuant to sales registered or exempted under the Securities Act.

 

    	 	12	 

     

    

 

Section 5.Miscellaneous.

 

a)     
No Rights as Stockholder Until Exercise. This Warrant does not entitle the Holder to any voting rights, dividends
or other rights as a stockholder of the Company prior to the exercise hereof as set forth in Section 2(d)(i), except as expressly
set forth in Section 3.

 

b)     
Loss, Theft, Destruction or Mutilation of Warrant. The Company covenants that upon receipt by the Company of evidence
reasonably satisfactory to it of the loss, theft, destruction or mutilation of this Warrant or any stock certificate relating to
the Warrant Shares, and in case of loss, theft or destruction, of indemnity or security reasonably satisfactory to it (which, in
the case of the Warrant, shall not include the posting of any bond), and upon surrender and cancellation of such Warrant or stock
certificate, if mutilated, the Company will make and deliver a new Warrant or stock certificate of like tenor and dated as of such
cancellation, in lieu of such Warrant or stock certificate.

 

c)     
Saturdays, Sundays, Holidays, etc. If the last or appointed day for the taking of any action or the expiration of
any right required or granted herein shall not be a Business Day, then, such action may be taken or such right may be exercised
on the next succeeding Business Day.

 

d)    
Authorized Shares.

 

1.                 
During the period the Warrant is outstanding from and after the Initial Exercise Date, the Company covenants that it will
reserve from its authorized and unissued Common Stock a sufficient number of shares to provide for the issuance of the Warrant
Shares upon the exercise of any purchase rights under this Warrant. The Company further covenants that its issuance of this Warrant
shall constitute full authority to its officers who are charged with the duty of issuing the necessary Warrant Shares upon the
exercise of the purchase rights under this Warrant. The Company will take all such reasonable action as may be necessary to assure
that such Warrant Shares may be issued as provided herein without violation of any applicable law or regulation, or of any requirements
of the Trading Market upon which the Common Stock may be listed. The Company covenants that all Warrant Shares which may be issued
upon the exercise of the purchase rights represented by this Warrant will, upon exercise of the purchase rights represented by
this Warrant and payment for such Warrant Shares in accordance herewith, be duly authorized, validly issued, fully paid and nonassessable
and free from all taxes, liens and charges created by the Company in respect of the issue thereof (other than taxes in respect
of any transfer occurring contemporaneously with such issue).

 

2.                 
Except and to the extent as waived or consented to by the Holder, the Company shall not by any action, including, without
limitation, amending its certificate of incorporation or through any reorganization, transfer of assets, consolidation, merger,
dissolution, issue or sale of securities or any other voluntary action, avoid or seek to avoid the observance or performance of
any of the terms of this Warrant, but will at all times in good faith assist in the carrying out of all such terms and in the taking
of all such actions as may be necessary or appropriate to protect the rights of Holder as set forth in this Warrant against impairment.
Without limiting the generality of the foregoing, the Company will (i) not increase the par value of any Warrant Shares above the
amount payable therefor upon such exercise immediately prior to such increase in par value, (ii) take all such action as may be
necessary or appropriate in order that the Company may validly and legally issue fully paid and nonassessable Warrant Shares upon
the exercise of this Warrant and (iii) use commercially reasonable efforts to obtain all such authorizations, exemptions or consents
from any public regulatory body having jurisdiction thereof, as may be, necessary to enable the Company to perform its obligations
under this Warrant.

 

    	 	13	 

     

    

 

3.                 
Before taking any action which would result in an adjustment in the number of Warrant Shares for which this Warrant is exercisable
or in the Exercise Price, the Company shall obtain all such authorizations or exemptions thereof, or consents thereto, as may be
necessary from any public regulatory body or bodies having jurisdiction thereof.

 

e)     
Jurisdiction. All questions concerning the construction, validity, enforcement and interpretation of this Warrant
shall be determined in accordance with the provisions of the Warrant Exercise Agreement.

 

f)      
Restrictions. The Holder acknowledges that the Warrant Shares acquired upon the exercise of this Warrant, if not
registered and the Holder does not utilize cashless exercise, will have restrictions upon resale imposed by state and federal securities
laws.

 

g)     
Nonwaiver and Expenses. No course of dealing or any delay or failure to exercise any right hereunder on the part
of Holder shall operate as a waiver of such right or otherwise prejudice the Holder’s rights, powers or remedies, notwithstanding
the fact that all rights hereunder terminate on the Termination Date. If the Company willfully and knowingly fails to comply with
any provision of this Warrant, which results in any material damages to the Holder, the Company shall pay to the Holder such amounts
as shall be sufficient to cover any costs and expenses including, but not limited to, reasonable attorneys’ fees, including
those of appellate proceedings, incurred by the Holder in collecting any amounts due pursuant hereto or in otherwise enforcing
any of its rights, powers or remedies hereunder.

 

h)     
Notices. Any notice, request or other document required or permitted to be given or delivered to the Holder by the
Company shall be delivered in accordance with the notice provisions of the Warrant Exercise Agreement.

 

i)       
Limitation of Liability. No provision hereof, in the absence of any affirmative action by the Holder to exercise
this Warrant to purchase Warrant Shares, and no enumeration herein of the rights or privileges of the Holder, shall give rise to
any liability of the Holder for the purchase price of any Common Stock or as a stockholder of the Company, whether such liability
is asserted by the Company or by creditors of the Company.

 

    	 	14	 

     

    

 

j)       
Remedies. The Holder, in addition to being entitled to exercise all rights granted by law, including recovery of
damages, will be entitled to specific performance of its rights under this Warrant. The Company agrees that monetary damages would
not be adequate compensation for any loss incurred by reason of a breach by it of the provisions of this Warrant and hereby agrees
to waive and not to assert the defense in any action for specific performance that a remedy at law would be adequate.

 

k)     
Successors and Assigns. Subject to applicable securities laws, this Warrant and the rights and obligations evidenced
hereby shall inure to the benefit of and be binding upon the successors and permitted assigns of the Company and the successors
and permitted assigns of Holder. The provisions of this Warrant are intended to be for the benefit of any Holder from time to time
of this Warrant and shall be enforceable by the Holder or holder of Warrant Shares.

 

l)       
Amendment. This Warrant may be modified or amended or the provisions hereof waived with the written consent of the
Company and the Holder.

 

m)   
Severability. Wherever possible, each provision of this Warrant shall be interpreted in such manner as to be effective
and valid under applicable law, but if any provision of this Warrant shall be prohibited by or invalid under applicable law, such
provision shall be ineffective to the extent of such prohibition or invalidity, without invalidating the remainder of such provisions
or the remaining provisions of this Warrant.

 

n)     
Headings. The headings used in this Warrant are for the convenience of reference only and shall not, for any purpose,
be deemed a part of this Warrant.

 

********************

(Signature Page Follows)

 

 

 

 

 

    	 	15	 

     

    

 

IN WITNESS WHEREOF, the Company has caused this
Warrant to be executed by its officer thereunto duly authorized as of the date first above indicated.

 

	 	AMYRIS, INC.
	 	 	 
	 	 	 
	 	By:	 
	 	 	Name: Kathleen Valiasek
	 	 	Title: Chief Financial Officer

 

 

 

 

 

 

 

 

 

    	 	16	 

     

    

 

NOTICE OF EXERCISE

 

To:AMYRIS, INC.

 

(1)  
The undersigned hereby elects to purchase ________ Warrant Shares of the Company pursuant to the terms of the attached Warrant
(only if exercised in full), and tenders herewith payment of the exercise price in full, together with all applicable transfer
taxes, if any.

 

(2)  
Applicable Exercise Price: $

 

(3)  
Payment shall take the form of (check applicable box):

 

[ ] in lawful money of the United States; or

 

[ ] the cancellation of such number of Warrant Shares
as is necessary, in accordance with the formula set forth in subsection 2(c), to exercise this Warrant with respect to the maximum
number of Warrant Shares purchasable pursuant to the cashless exercise procedure set forth in subsection 2(c).

 

(4)  
Please issue said Warrant Shares in the name of the undersigned or in such other name as is specified below:

 

_______________________________

 

 

The Warrant Shares shall be delivered to the following DWAC Account
Number:

 

_______________________________

 

_______________________________

 

_______________________________

 

(4) Accredited Investor. The undersigned
is an “accredited investor” as defined in Regulation D promulgated under the Securities Act of 1933, as amended.

 

[SIGNATURE OF HOLDER]

 

	Name of Investing Entity:	 

	Signature of Authorized Signatory of Investing Entity: 	 

	Name of Authorized Signatory: 	   
	Title of Authorized Signatory:	 

	Date: 	 

 

 

 

    	 	17	 

     

    

 

ASSIGNMENT FORM

(To assign the foregoing Warrant, execute this form and supply
required information. Do not use this form to purchase shares.)

 

FOR VALUE RECEIVED, the foregoing Warrant and all rights evidenced
thereby are hereby assigned to

 

	Name:	 	 	 
	 	 	 	(Please Print)
	Address:	 	 	 
	 	 	 	(Please Print)
	Phone Number:	 	 	 
	Email Address: 	 	 	 
	Dated: _______________ __, ______	 	 
	Holder’s Signature:	 	 	 
	Holder’s Address:	 	 	 

 

 

 

    	 	18	 

     

    

 

Exhibit B

 

 

 

 

 

 

 

 

 

 

 

 

    	 	19	 

     

    

 

NOTICE OF EXERCISE

 

To:AMYRIS, INC.

 

(1)  
The undersigned hereby elects to purchase ________ Warrant Shares of the Company pursuant to the terms of the attached Warrant
(only if exercised in full), and tenders herewith payment of the exercise price in full, together with all applicable transfer
taxes, if any.

 

(2)  
Applicable Exercise Price: $

 

(3)  
Payment shall take the form of (check applicable box):

 

[ ] in lawful money of the United States;
or

 

[ ] [the cancellation of such number
of Warrant Shares as is necessary, in accordance with the formula set forth in subsection 2(c), to exercise this Warrant with respect
to the maximum number of Warrant Shares purchasable pursuant to the cashless exercise procedure set forth in subsection 2(c).

 

(4)  
Please issue said Warrant Shares in the name of the undersigned or in such other name as is specified below:

 

_______________________________

 

 

The Warrant Shares shall be delivered to the following DWAC Account Number:

 

_______________________________

 

_______________________________

 

_______________________________

 

(4) Accredited Investor. The undersigned is an “accredited
investor” as defined in Regulation D promulgated under the Securities Act of 1933, as amended.

 

[SIGNATURE OF HOLDER]

 

	Name of Investing Entity:	 

	Signature of Authorized Signatory of Investing Entity: 	 

	Name of Authorized Signatory: 	   
	Title of Authorized Signatory:	 

	Date:EXHIBIT 10.3

 

WARRANT EXERCISE AGREEMENT

 

This Warrant Exercise Agreement (this “Agreement”)
is dated as of August 17, 2018 (the “Effective Date”), among Amyris, Inc., a Delaware corporation (the “Company”)
and the undersigned investor (the “Holder”).

 

WHEREAS,
reference is hereby made to that certain Securities Purchase Agreement, dated August 2, 2017 (the “Securities Purchase
Agreement”), by and among the Company and the investors party thereto (including the Holder, the “Holders”),
pursuant to which, among other things, the Holder acquired (a) a Common Stock Purchase Warrant, with an exercise price as of the
date hereof of $4.40 per share of common stock of the Company, par value $0.0001 per share (the “Common Stock”),
exercisable as of the date hereof into such aggregate number of shares of Common Stock as set forth on the signature page of the
Holder attached hereto (the “Cash Warrant”, as exercised, the “Cash Warrant Shares”) and
(b) a Common Stock Purchase Warrant, with an exercise price of $0.0001 per share of Common Stock, exercisable as of the date hereof
into such aggregate number of shares of Common Stock as set forth on the signature page of the Holder attached hereto (the “Dilution
Warrant”). Capitalized terms not defined herein shall have the meaning as set forth in the Securities Purchase Agreement
or the Cash Warrant, as applicable.

 

WHEREAS,
subject to the terms and conditions set forth in this Agreement and in reliance upon the exemption from securities registration
afforded by Section 4(a)(2) of the Securities Act of 1933, as amended (the “Securities Act”), and Rule 506(b)
of Regulation D (“Regulation D”) as promulgated by the United States Securities and Exchange Commission
(the “SEC”) under the Securities Act, as consideration for (a) the cash exercise of the Cash Warrant into the
applicable aggregate number of Cash Warrant Shares as set forth on the signature page of the Holder attached hereto (such number,
as applicable, the “Cash Warrant Share Exercise Amount”) and (b) the cancellation of the Dilution Warrant, the
Company shall issue to the Holder new Common Stock Purchase Warrants, in the form attached hereto as Exhibit A (collectively,
the “New Warrant”), initially exercisable into an aggregate of 876,000 shares of Common Stock (the “New
Warrant Shares”, and together with the New Warrant, the “New Securities”, and together with this Agreement,
the “Transaction Documents”).

 

WHEREAS,
concurrently herewith, the Company is entering into agreements with certain other Holders (each, an “Other Holder”)
of Common Stock Purchase Warrants issued pursuant to the Securities Purchase Agreement (each, an “Other Warrant”
and such agreements, each an “Other Agreement”) substantially in the form of this Agreement.

 

NOW, THEREFORE,
in consideration of the mutual covenants contained in this Agreement, and for other good and valuable consideration the receipt
and adequacy of which are hereby acknowledged, the Company and the Holder agree as follows:

 

1.                 
Exercise of Cash Warrant; Cancellation of Dilution Warrant.

 

     

    

    

 

(a)               
General. On the date hereof and at the Applicable Time (as defined in that certain Underwriting Agreement, dated
as of the Closing Date (as defined below) by and between the Company, B. Riley FBR, Inc., as the “Underwriter”,
and the Selling Stockholders (including Holder) listed on Schedule I thereto (the “Underwriting Agreement”))
and simultaneously with the transactions contemplated by clauses (ii) and (iii) of this Section 1(a) (the “Initial Exercise”
and the “Initial Exercise Date”) and, if a Second Exercise (as defined below) is triggered as a result of B.
Riley FBR, Inc. electing to exercise its option to purchase more shares of the Company’s Common Stock from the Holder pursuant
to the Underwriting Agreement (i) the Holder shall duly execute and deliver to the Company an irrevocable Notice of Exercise, in
the form attached hereto as Exhibit B (the “Notice of Exercise”) and, on or prior to the Delivery
Date (as defined below), shall wire, or shall cause to be wired (directly or indirectly) the payment of the aggregate exercise
price of the applicable Cash Warrant Share Exercise Amount of the Cash Warrant, as set forth on the signature page of the Holder
attached hereto, to the Company in accordance with the wire instructions of the Company (or the wire instructions of another party
designated by the Company) communicated to the Holder (or other relevant party making payment on behalf of the Holder) at least
one (1) Business Day prior to the (Y) date hereof in the case of the Initial Exercise and (Z) Second Exercise Date in case of the
Second Exercise (each such date, the “Closing Date” with regard to such exercise), in U.S. dollars and immediately
available funds, to effect the exercise of the applicable Cash Warrant Share Exercise Amount of the Cash Warrant, (ii) the Dilution
Warrant shall be deemed cancelled immediately on the Closing Date associated with the Initial Exercise Date and simultaneously
with the transactions contemplated by clauses (i) and (iii) of this Section 1(a) and, as promptly as commercially practicable after
the Effective Date, the Dilution Warrant shall be delivered to the Company at the address set forth in Section 5(h) hereof (provided,
that to the extent such Dilution Warrant was exercised, in whole or in part, on or prior to the Closing Date prior to its deemed
cancellation, such Dilution Warrant shall remain in full force and effect until the shares of Common Stock owed to the Holder in
such exercise(s) are delivered to the Holder (or its designee), as applicable), and (iii) the Company shall duly execute and issue
to the Holder the New Warrant on the Closing Date and simultaneously with the transactions contemplated by clauses (i) and (ii)
of this Section 1(a), initially exercisable into 876,000 New Warrant Shares (collectively, the “Closing”, and
such transactions, the “Transactions”). The Company shall deliver the New Warrant to the Holder as soon as commercially
practicable following the applicable Closing Date to the address set forth on the signature page of the Holder attached hereto
(or such other address as designated by the Holder in writing to the Company). Notwithstanding anything herein to the contrary,
if the Holder elects on its signature page to have the lock up provisions included as Annex I attached hereto apply
to the Holder, the Holder: (i) will be prohibited from selling or otherwise transferring for value the Cash Warrant Share Exercise
Amount of Cash Warrant Shares to be delivered to the Holder (or its designee) in accordance with the Notice of Exercise during
the period beginning on the applicable Closing Date and continuing to and including the date 180 days after such Closing Date,
and (ii) shall be entitled to effect the exercise of the Cash Warrant pursuant to a cashless exercise in accordance therewith in
lieu of the Holder’s obligations to exercise the Cash Warrant in cash in accordance therewith and herewith. If the Underwriter
exercises its option under the Underwriting Agreement to purchase the Optional Shares (as defined in the Underwriting Agreement),
then Holder will execute another irrevocable Notice of Exercise (a “Second Exercise”), and deliver such Notice
of Exercise to the Company (the date of such delivery, the “Second Exercise Date”) and there shall be a second
Closing as set forth in this paragraph.

 

(b)              
Delivery of Cash Warrant Shares. No later than the second (2nd) Trading Day after the applicable Closing Date (the
“Delivery Date”) the Company shall cause the applicable Cash Warrant Share Exercise Amount of Cash Warrant Shares
to be delivered to the Holder (or its designee) in accordance with the Cash Warrant and the deposit/withdrawal at custodian or
other delivery instructions set forth in the Notice of Exercise applicable to such exercise.

 

    	2

    

    

 

(c)               
Return of Certificates. As promptly as practicable after the applicable Closing Date, the Holder shall return to
the Company the certificate evidencing (i) the Dilution Warrant (or a lost warrant affidavit in form and substance satisfactory
to the Company), which shall automatically be deemed cancelled and null and void upon the consummation of the Closing; and (ii)
solely if the Cash Warrant is exercised in full pursuant to the Notice of Exercise, the Cash Warrant.

 

2.                 
Representations and Warranties of Company. Except as set forth in the Disclosure Schedules, which Disclosure Schedules
shall be deemed a part hereof and shall qualify any representation or warranty otherwise made herein to the extent of the disclosure
contained in the corresponding section of the Disclosure Schedules, the Company hereby makes the following representations and
warranties to the Holder:

 

(a)               
Organization and Standing. The Company and each of its subsidiaries is duly incorporated, validly existing, and in
good standing under the laws of the jurisdiction of its organization. Each of the Company and its subsidiaries has all requisite
power and authority to own and operate its respective properties and assets and to carry on its respective business as presently
conducted and as proposed to be conducted. The Company and each of its subsidiaries is qualified to do business as a foreign entity
in every jurisdiction in which the failure to be so qualified would have, or would reasonably be expected to have, a material adverse
effect, individually or in the aggregate, upon the business, properties, tangible and intangible assets, liabilities, operations,
prospects, financial condition or results of operation of the Company and its subsidiaries or the ability of the Company or any
of its subsidiaries to perform their respective obligations under the Transaction Documents (a “Material Adverse Effect”).

 

(b)              
Power. The Company has all requisite power to execute and deliver this Agreement, to sell and issue the New Securities
hereunder, and to carry out and perform its obligations under the terms of the Transaction Documents.

 

(c)               
Authorization. The execution, delivery, and performance of the Transaction Documents by the Company has been duly
authorized by all requisite action on the part of the Company and its officers, directors and stockholders, and this Agreement
constitutes, and the other Transaction Documents will constitute, legal, valid, and binding obligations of the Company enforceable
in accordance with their terms, except (a) as limited by applicable bankruptcy, insolvency, reorganization, moratorium, and other
laws of general application affecting enforcement of creditors’ rights generally, and (b) as limited by laws relating to
the availability of specific performance, injunctive relief or other equitable remedies (together, the “Enforceability
Exceptions”).

 

(d)              
Consents and Approvals. Except for any Current Report on Form 8-K or Notice of Exempt Offering of Securities on Form
D to be filed by the Company in connection with the transactions contemplated hereby, or except as set forth on Section 2(d) of
the Disclosure Schedules, the Company is not required to give any notice to, make any filing with, or obtain any authorization,
consent, or approval of any government or governmental agency in order to consummate the transactions contemplated by the Transaction
Documents. Assuming the accuracy of the representations of the Holder set forth herein, no consent, approval, authorization or
other order of, or registration, qualification or filing with, any court, regulatory body, administrative agency, self-regulatory
organization, stock exchange or market (including The NASDAQ Stock Market), or other governmental body is required for the execution
and delivery of the Transaction Documents, the valid issuance, sale and delivery of the New Securities to be sold pursuant to this
Agreement other than such as have been made or obtained, or for any securities filings required to be made under federal or state
securities laws applicable to the offering of the New Securities.

 

    	3

    

    

 

(e)               
Non-Contravention. The execution and delivery of the Transaction Documents, the issuance, sale and delivery of the
New Securities to be sold by the Company under this Agreement, the performance by the Company of its obligations under the Transaction
Documents and/or the consummation of the transactions contemplated thereby will not (i) conflict with, result in the breach or
violation of, or constitute (with or without the giving of notice or the passage of time or both) a violation of, or default under,
(A) any bond, debenture, note or other evidence of indebtedness, or under any lease, license, franchise, permit, indenture, mortgage,
deed of trust, loan agreement, joint venture or other agreement or instrument to which the Company or any subsidiary is a party
or by which it or its properties may be bound or affected, (B) the Company’s Restated Certificate of Incorporation, as amended
and as in effect on the date hereof (the “Certificate of Incorporation”), the Company’s Bylaws, as amended
and as in effect on the date hereof (the “Bylaws”), or the equivalent document with respect to any subsidiary,
as amended and as in effect on the date hereof, or (C) any statute or law, judgment, decree, rule, regulation, ordinance or order
of any court or governmental or regulatory body (including The NASDAQ Stock Market), governmental agency, arbitration panel or
authority applicable to the Company, any of its subsidiaries or their respective properties, except in the case of clauses (A)
and (C) for such conflicts, breaches, violations or defaults that would not be likely to have, individually or in the aggregate,
a Material Adverse Effect, or (ii) result in the creation or imposition of any lien, encumbrance, claim, security interest or restriction
whatsoever upon any of the material properties or assets of the Company or any of its subsidiaries or an acceleration of indebtedness
pursuant to any obligation, agreement or condition contained in any material bond, debenture, note or any other evidence of indebtedness
or any material indenture, mortgage, deed of trust or any other agreement or instrument to which the Company or any if its subsidiaries
is a party or by which the Company or any of its subsidiaries is bound or to which any of the property or assets of the Company
is subject. For purposes of this Section 2(e), the term “material” shall apply to agreements, understandings, instruments,
contracts or proposed transactions to which the Company is a party or by which it is bound involving obligations (contingent or
otherwise) of, or payments to, the Company in excess of $100,000 in a consecutive 12-month period.

 

(f)               
Authorization of the New Securities. The New Warrants have been duly authorized by the Company and, when duly executed
and delivered by the Company, will constitute a valid and binding agreement of the Company, enforceable against the Company in
accordance with its terms, subject to the Enforceability Exceptions. The New Warrant Shares issuable upon exercise of the New Warrants
have been, duly authorized and reserved for issuance upon exercise by all necessary corporate action and such shares, when issued
upon such exercise in accordance of the terms of the New Warrants, will be validly issued and will be fully paid and non-assessable,
and will be free of any liens or encumbrances with respect to the issuance thereof; provided, however, that the New Warrant Shares
shall be subject to restrictions on transfer under state or federal securities laws as set forth in this Agreement, or as otherwise
may be required under state or federal securities laws as set forth in this Agreement at the time a transfer is proposed. Except
as set forth on Section 2(f) of the Disclosure Schedules, the issuance and delivery of the New Warrant Shares is not subject to
preemptive, co-sale, right of first refusal or any other similar rights of the stockholders of the Company or any other Person,
or any liens or encumbrances or result in the triggering of any anti-dilution or other similar rights under any outstanding securities
of the Company.

 

    	4

    

    

 

(g)              
Registration. Assuming the accuracy of each of the representations and warranties of the Holder herein, the issuance
by the Company of the New Securities is exempt from registration under the Securities Act. The Company has prepared and filed a
registration statement (Registration No. 333-221351) (the “Registration Statement”) in conformity with the requirements
of the Securities Act, which became effective on December 1, 2017 (the “Warrant Effective Date”), including
a prospectus, dated December 5, 2017 (the “Prospectus”) for, among other things, the resale by the Holder of
the Cash Warrant Shares, and such amendments and supplements thereto as may have been required to the date of this Agreement. The
Registration Statement is effective under the Securities Act and no stop order preventing or suspending the effectiveness of the
Registration Statement or suspending or preventing the use of the Prospectus has been issued by the Commission and no proceedings
for that purpose have been instituted or, to the knowledge of the Company, are threatened by the Commission. At the time the Registration
Statement and any amendments thereto became effective and at the date of this Agreement, the Registration Statement and any amendments
thereto conformed and will conform in all material respects to the requirements of the Securities Act and did not and will not
contain any untrue statement of a material fact or omit to state any material fact required to be stated therein or necessary to
make the statements therein not misleading; and the Prospectus and any amendments or supplements thereto, at the time the Prospectus
or any amendment or supplement thereto was issued and as of the date hereof, conformed and will conform in all material respects
to the requirements of the Securities Act and did not and will not contain an untrue statement of a material fact or omit to state
a material fact necessary in order to make the statements therein, in light of the circumstances under which they were made, not
misleading. The Company was at the time of the filing of the Registration Statement eligible to use Form S-3.

 

(h)              
Capitalization. As of the date hereof, the authorized capital stock of the Company consists of (a) 250,000,000 shares
of Common Stock, 50,383,859 shares of which are issued and outstanding as of the date hereof, and (b) 5,000,000 shares of Preferred
Stock, $0.0001 par value per share, of which 22,140 shares have been designated as Series A 17.38% Convertible Preferred Stock,
105,204 shares have been designated as Series B 17.38% Convertible Preferred Stock, 20,921 shares have been designated as Series
C Convertible Preferred Stock and 15,000 shares have been designated as Series D Convertible Preferred Stock, and of which there
are no shares of Series A 17.38% Convertible Preferred Stock, 6,376.2787 shares of Series B 17.38% Convertible Preferred Stock,
no shares of Series C Convertible Preferred Stock and 12,958.21196 shares of Series D Convertible Preferred Stock issued and outstanding
as of the date hereof. All subscriptions, warrants, options, convertible securities, and other rights (contingent or other) to
purchase or otherwise acquire equity securities of the Company issued and outstanding as of the date hereof, or contracts, commitments,
understandings, or arrangements by which the Company or any of its subsidiaries is or may be obligated to issue shares of capital
stock, or securities or rights convertible or exchangeable for shares of capital stock, other than the New Securities, are as set
forth in the SEC Documents. Taking into account all rights and agreements described in the immediately preceding sentence and any
applicable anti-dilution provisions in any such agreement, immediately after the Closing and after giving effect to the consummation
of this offering of the New Securities, there will be (i) 64,040,753 shares of Common Stock issued and outstanding and (ii) a maximum
of 57,870,205 shares of Common Stock issuable upon conversion, exchange or exercise of all outstanding securities of the Company
(including, without limitation, all Common Stock Equivalents) that are convertible into, exercisable or exchangeable for, settled
in, or may be paid or repaid with, shares of Common Stock. The issued and outstanding shares of the Company’s capital stock
have been duly authorized and validly issued, are fully paid and nonassessable, have been issued in compliance with all applicable
federal and state securities laws, and were not issued in violation of or subject to any preemptive rights or other rights to subscribe
for or purchase securities. Except as set forth in Section 2(h) of the Disclosure Schedules, no holder of the Company’s capital
stock is entitled to preemptive or similar rights in connection with the issuance of the New Securities. Except as set forth in
or incorporated by reference into the SEC Documents filed with the SEC on or after December 31, 2017, but prior to the date hereof,
there are no bonds, debentures, notes or other indebtedness having general voting rights (or convertible into securities having
such rights) of the Company issued and outstanding. Except as set forth in or incorporated by reference into the SEC Documents
filed with the SEC on or after December 31, 2017, but prior to the date hereof, there are no agreements or arrangements under which
the Company or any of its subsidiaries is obligated to register the sale of any of their securities under the Securities Act. The
Company has made available to the Holder, a true, correct and complete copy of the Company’s Certificate of Incorporation
and Bylaws. From August 3, 2017 to the time of execution of this Agreement, the Company has not issued or sold any Common Stock
or Common Stock Equivalents at a price (or exercise, conversion or exchange price, as applicable) per share of Common Stock less
than $4.26, other than in respect of an Exempt Issuance.

 

    	5

    

    

 

(i)                
Legal Proceedings. Except as set forth in or incorporated by reference into the SEC Documents filed with the SEC
on or after December 31, 2017, but prior to the date hereof, there is no Proceeding before any court, governmental agency or body,
domestic or foreign, now pending or, to the knowledge of the Company, threatened against the Company or its subsidiaries wherein
an unfavorable decision, ruling or finding would reasonably be expected to, individually or in the aggregate, (i) materially adversely
affect the validity or enforceability of, or the authority or ability of the Company to perform its obligations under, this Agreement
or (ii) have a Material Adverse Effect. The Company is not a party to or subject to the provisions of any injunction, judgment,
decree or order of any court, regulatory body, administrative agency or other governmental agency or body that might have, individually
or in the aggregate, a Material Adverse Effect.

 

(j)                
No Violations. Neither the Company nor any of its subsidiaries is in violation of its respective certificate of incorporation,
bylaws or other organizational documents, or to its knowledge, is in violation of any statute or law, judgment, decree, rule, regulation,
ordinance or order of any court or governmental or regulatory body (including The NASDAQ Stock Market), governmental agency, arbitration
panel or authority applicable to the Company or any of its subsidiaries, which violation, individually or in the aggregate, would
be reasonably likely to have a Material Adverse Effect. Neither the Company nor any of its subsidiaries is in default (and there
exists no condition which, with or without the passage of time or giving of notice or both, would constitute a default) in the
performance of any bond, debenture, note or any other evidence of indebtedness in any indenture, mortgage, deed of trust or any
other material agreement or instrument to which the Company or any of its subsidiaries is a party or by which the Company or any
of its subsidiaries is bound or by which the properties of the Company are bound, which would be reasonably likely to have a Material
Adverse Effect. There has not been, and to the knowledge of the Company, there is not pending or contemplated, any investigation
by the Commission involving the Company or any current or former director or officer of the Company and the Company is not an “ineligible
issuer” pursuant to Rules 164, 405 and 433 under the Securities Act. The Company has not received any comment letter from
the Commission relating to any SEC Documents which has not been finally resolved. The Commission has not issued any stop order
or other order suspending the effectiveness of any registration statement filed by the Company under the Exchange Act or the Securities
Act.

 

    	6

    

    

 

(k)              
Listing Compliance. The Company is in compliance with the requirements of The NASDAQ Stock Market LLC for continued
listing of the Common Stock thereon and has no knowledge of any facts or circumstances that could reasonably lead to delisting
of its Common Stock from The NASDAQ Stock Market. The Company has taken no action designed to, or likely to have the effect of,
terminating the registration of the Common Stock under the Exchange Act or the listing of the Common Stock on The NASDAQ Stock
Market, nor has the Company received any notification that the Commission or The NASDAQ Stock Market is contemplating terminating
such registration or listing. The transactions contemplated by the Transaction Documents will not contravene the rules and regulations
of The NASDAQ Stock Market. The Company will comply with all requirements of The NASDAQ Stock Market with respect to the issuance
of the New Securities, including the filing of any listing notice with respect to the issuance of the New Securities.

 

(l)                
Integration; Other Issuances of Securities. Except as set forth in Section 2(l) of the Disclosure Schedules, neither
the Company nor its subsidiaries or any Affiliates, nor any Person acting on its or their behalf, has issued any shares of Common
Stock or shares of any series of preferred stock or other securities or instruments convertible into, exchangeable for or otherwise
entitling the holder thereof to acquire shares of Common Stock which would be integrated with the sale or exchange of the New Securities
to the Holder for purposes of the Securities Act or of any applicable stockholder approval provisions, including, without limitation,
under the rules and regulations of The NASDAQ Stock Market, nor will the Company or its subsidiaries or Affiliates take any action
or steps that would require registration of any of the New Securities under the Securities Act or cause the offering of the New
Securities to be integrated with other offerings if any such integration would cause the issuance of the New Securities hereunder
to fail to be exempt from registration under the Securities Act or cause the transactions contemplated hereby to contravene the
rules and regulations of The NASDAQ Stock Market. The Company is eligible to register the New Warrant Shares for resale by the
Holder using Form S-3 promulgated under the Securities Act.

 

(m)            
No General Solicitation. Neither the Company nor its subsidiaries or any Affiliates, nor any Person acting on its
or their behalf, has offered or sold any of the New Securities by any form of general solicitation or general advertising.

 

    	7

    

    

 

(n)              
No Brokers’ Fees. Except as set forth in Section 2(n) of the Disclosure Schedules, the Company has not incurred
any liability for any finder’s or broker’s fee or agent’s commission in connection with the execution and delivery
of this Agreement or the consummation of the transactions contemplated hereby.

 

(o)              
Acknowledgment Regarding Holder’s Purchase of Securities. The Company acknowledges and agrees that the Holder
is acting solely in the capacity of an arm’s length purchaser with respect to the Transaction Documents and the transactions
contemplated thereby. The Company further acknowledges that the Holder is not acting as a financial advisor or fiduciary of the
Company (or in any similar capacity) with respect to the Transaction Documents and the transactions contemplated thereby and any
advice given by the Holder or any of its representatives or agents in connection with the Transaction Documents and the transactions
contemplated thereby is merely incidental to the Holder’s purchase of the New Securities. The Company further represents
to the Holder that the Company’s decision to enter into this Agreement and the other Transaction Documents has been based
solely on the independent evaluation of the transactions contemplated hereby by the Company and its representatives.

 

(p)              
No Disqualification. No “bad actor” disqualifying event described in Rule 506(d)(1)(i)-(viii) of the
Securities Act (a “Disqualification Event”) is applicable to the Company or, to the Company’s knowledge,
any Company Covered Person, except for a Disqualification Event as to which Rule 506(d)(2)(ii–iv) or (d)(3), is applicable.
As used herein, “Company Covered Person” means, with respect to the Company as an “issuer” for purposes
of Rule 506 promulgated under the Securities Act, any Person listed in the first paragraph of Rule 506(d)(1).

 

(q)              
Disclosure. Except with respect to the material terms and conditions of the transactions contemplated by the Transaction
Documents, the Company confirms that neither it nor any other Person acting on its behalf has provided the Holder or its agents
or counsel with any information that it believes constitutes material, non-public information which will not otherwise be disclosed
in that certain Prospectus Supplement filed by the Company on August 16, 2018. All disclosure furnished by or on behalf of the
Company to the Holder in connection with this Agreement regarding the Company, its business and the transactions contemplated hereby
is true and correct in all material respects and does not contain any untrue statement of a material fact or omit to state any
material fact necessary in order to make the statements made therein, in light of the circumstances under which they were made,
not misleading. The Company acknowledges and agrees that the Holder has not made and does not make any representations or warranties
with respect to the transactions contemplated hereby other than those set forth in Article 3 hereto.

 

3.                 
Representations and Warranties of the Holder. The Holder hereby represents and warrants as of the date hereof
(and, where specified, as of the applicable Closing Date) to the Company as follows (unless as of a specific date therein, in which
case they shall be accurate as of such date):

 

(a)               
Organization; Authority. The Holder is either an individual or an entity duly incorporated or formed, validly existing
and in good standing under the laws of the jurisdiction of its incorporation or formation with full right, corporate, partnership,
limited liability company or similar power and authority to enter into and to consummate the transactions contemplated by the Transaction
Documents and otherwise to carry out its obligations hereunder and thereunder. The execution and delivery of the Transaction Documents
and performance by the Holder of the transactions contemplated by the Transaction Documents have been duly authorized by all necessary
corporate, partnership, limited liability company or similar action, as applicable, on the part of the Holder. Each Transaction
Document to which it is a party has been duly executed by the Holder, and when delivered by the Holder in accordance with the terms
hereof, will constitute the valid and legally binding obligation of the Holder, enforceable against it in accordance with its terms,
except: (i) as limited by general equitable principles and applicable bankruptcy, insolvency, reorganization, moratorium and other
laws of general application affecting enforcement of creditors’ rights generally, (ii) as limited by laws relating to the
availability of specific performance, injunctive relief or other equitable remedies and (iii) insofar as indemnification and contribution
provisions may be limited by applicable law.

 

    	8

    

    

 

(b)              
Understandings or Arrangements. The Holder is acquiring the New Securities as principal for its own account and has
no direct or indirect arrangement or understandings with any other persons to distribute or regarding the distribution of such
New Securities (this representation and warranty not limiting the Holder’s right to sell the Cash Warrant Shares pursuant
to the Registration Statement or otherwise in compliance with applicable federal and state securities laws). The Holder is acquiring
the New Securities hereunder in the ordinary course of its business. The Holder understands that the New Securities are “restricted
securities” and have not been registered under the Securities Act or any applicable state securities law and is acquiring
such New Securities as principal for his, her or its own account and not with a view to or for distributing or reselling such New
Securities or any part thereof in violation of the Securities Act or any applicable state securities law, has no present intention
of distributing any of such New Securities in violation of the Securities Act or any applicable state securities law and has no
direct or indirect arrangement or understandings with any other persons to distribute or regarding the distribution of such New
Securities in violation of the Securities Act or any applicable state securities law (this representation and warranty not limiting
the Holder’s right to sell the Cash Warrant Shares pursuant to the Registration Statement or otherwise in compliance with
applicable federal and state securities laws).

 

(c)               
Holder Status. At the time the Holder was offered the New Securities, it was, and as of the Closing Date it is, and
on each date on which it exercises any New Warrants, it will be an “accredited investor” as defined in Rule 501(a)(1),
(a)(2), (a)(3), (a)(7) or (a)(8) under the Securities Act.

 

(d)              
Experience of the Holder. The Holder, either alone or together with its representatives, has such knowledge, sophistication
and experience in business and financial matters so as to be capable of evaluating the merits and risks of the prospective investment
in the New Securities, and has so evaluated the merits and risks of such investment. The Holder is able to bear the economic risk
of an investment in the New Securities and, at the present time, is able to afford a complete loss of such investment.

 

(e)               
Access to Information. The Holder acknowledges that it has had the opportunity to review the Transaction Documents
(including all exhibits and schedules thereto) and the SEC Documents and has been afforded: (i) the opportunity to ask such questions
as it has deemed necessary of, and to receive answers from, representatives of the Company concerning the terms and conditions
of the offering of the New Securities and the merits and risks of investing in the New Securities; (ii) access to information about
the Company and its financial condition, results of operations, business, properties, management and prospects sufficient to enable
it to evaluate its investment; and (iii) the opportunity to obtain such additional information that the Company possesses or can
acquire without unreasonable effort or expense that is necessary to make an informed investment decision with respect to the investment.

 

    	9

    

    

 

(f)               
Confidentiality. Other than to other Persons party to this Agreement or to the Holder’s representatives, including,
without limitation, its officers, directors, partners, legal and other advisors, employees, agents and Affiliates, the Holder has
maintained the confidentiality of all disclosures made to it in connection with this transaction (including the existence and terms
of this transaction).

 

(g)              
General Solicitation. The Holder is not purchasing the New Securities as a result of any advertisement, article,
notice or other communication regarding the New Securities published in any newspaper, magazine or similar media or broadcast over
television or radio or presented at any seminar or, to the Holder’s knowledge, any other general solicitation or general
advertisement.

 

(h)              
Ownership of Cash Warrant and Dilution Warrant. The Holder owns the Cash Warrant and the Dilution Warrant, in each
case, free and clear of any Liens (other than the obligations pursuant to this Agreement, the Transaction Documents (as defined
in the Securities Purchase Agreement), the Underwriting Agreement, and applicable securities laws).

 

The Company acknowledges and agrees that the
representations contained in this Section 3 shall not modify, amend or affect the Holder’s right to rely on the Company’s
representations and warranties contained in this Agreement or any representations and warranties contained in any other Transaction
Document or any other document or instrument executed and/or delivered in connection with this Agreement or the consummation of
the transactions contemplated hereby. Notwithstanding the foregoing, for the avoidance of doubt, nothing contained herein shall
constitute a representation or warranty, or preclude any actions, with respect to locating or borrowing shares in order to effect
Short Sales or similar transactions in the future.

 

4.                 
Covenants.

 

(a)               
Removal of Legends. (i) The New Securities may only be disposed of in compliance with state and federal securities
laws. In connection with any transfer of New Securities other than pursuant to an effective registration statement or Rule 144,
to the Company or to an Affiliate of the Holder or in connection with a pledge as contemplated in Section 4(b), the Company may
require the transferor thereof to provide to the Company an opinion of counsel selected by the transferor and reasonably acceptable
to the Company, the form and substance of which opinion shall be reasonably satisfactory to the Company, to the effect that such
transfer does not require registration of such transferred New Securities under the Securities Act. The Holder agrees to the imprinting,
so long as is required by this Section 4(a), of a legend on any of the New Securities in the following form:

 

NEITHER THIS SECURITY NOR THE SECURITIES INTO WHICH THIS
SECURITY IS EXERCISABLE HAS BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE
IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”),
AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR
PURSUANT TO AN AVAILABLE EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT
AND IN ACCORDANCE WITH APPLICABLE STATE SECURITIES LAWS. THIS SECURITY AND THE SECURITIES ISSUABLE UPON EXERCISE OF THIS SECURITY
MAY BE PLEDGED IN CONNECTION WITH A BONA FIDE MARGIN ACCOUNT WITH A REGISTERED BROKER-DEALER OR OTHER LOAN WITH A FINANCIAL INSTITUTION
THAT IS AN “ACCREDITED INVESTOR” AS DEFINED IN RULE 501(a) UNDER THE SECURITIES ACT OR OTHER LOAN SECURED BY SUCH SECURITIES.

 

    	10

    

    

 

(ii) The Company acknowledges and agrees
that the Holder may from time to time pledge pursuant to a bona fide margin agreement with a registered broker-dealer or grant
a security interest in some or all of the New Securities to a financial institution that is an “accredited investor”
as defined in Rule 501(a) under the Securities Act and, if required under the terms of such arrangement, the Holder may transfer
pledged or secured New Securities to the pledgees or secured parties. Such a pledge or transfer would not be subject to approval
of the Company and no legal opinion of legal counsel of the pledgee, secured party or pledgor shall be required in connection therewith.
Further, no notice shall be required of such pledge. At the Holder’s expense, the Company will execute and deliver such reasonable
documentation as a pledgee or secured party of New Securities may reasonably request in connection with a pledge or transfer of
the New Securities.

 

(iii) Certificates evidencing the New
Securities shall not contain any legend: (A) while a registration statement covering the resale of such security is effective under
the Securities Act, (B) following any sale of such New Securities pursuant to Rule 144, (C) if such New Securities are eligible
for sale under Rule 144, or (D) if such legend is not required under applicable requirements of the Securities Act (including judicial
interpretations and pronouncements issued by the staff of the Commission). The Company shall cause its counsel to issue a legal
opinion to the Transfer Agent promptly if required by the Transfer Agent or requested by the Holder to effect the removal of the
legend hereunder. If all or a portion of the New Warrant is exercised at a time when there is an effective registration statement
to cover the resale of the applicable New Warrant Shares, or if such New Warrant Shares may be sold under Rule 144 or if such legend
is not otherwise required under applicable requirements of the Securities Act (including judicial interpretations and pronouncements
issued by the staff of the Commission) then such New Warrant Shares shall be issued free of all legends. The Company agrees that
following such time as such legend is no longer required under this Section 4(a) and upon the request of the Holder, the Company
will, no later than two Trading Days following the delivery by the Holder to the Transfer Agent (with simultaneous notice to the
Company pursuant to Section 5(h) hereof) of a certificate representing New Warrant Shares issued with a restrictive legend (such
second Trading Day, the “Legend Removal Date”), cause to be delivered to the Holder such shares that are free
from all restrictive and other legends by crediting the account of the Holder's prime broker with the Depository Trust Company
System as directed by the Holder. The Company may not make any notation on its records or give instructions to the Transfer Agent
that enlarge the restrictions on transfer set forth in this Section 4(a). New Warrant Shares subject to legend removal hereunder
shall be transmitted by the Transfer Agent to the Holder by crediting the account of the Holder’s prime broker with the Depository
Trust Company System as directed by the Holder.

 

    	11

    

    

 

(iv) In addition to the Holder’s
other available remedies, the Company shall pay to the Holder, in cash, (A) as partial liquidated damages and not as a penalty,
for each $1,000 of New Warrant Shares (based on the VWAP of the Common Stock on the date such New Securities are submitted to the
Transfer Agent) delivered for removal of the restrictive legend and subject to Section 4(a)(ii), $10 per Trading Day (increasing
to $20 per Trading Day five (5) Trading Days after such damages have begun to accrue) for each Trading Day commencing one Trading
Day after the Legend Removal Date until such certificate is delivered without a legend and (B) if the Company fails to (x) issue
and deliver (or cause to be delivered) to the Holder by the Legend Removal Date a certificate representing the New Securities so
delivered to the Company by the Holder that is free from all restrictive and other legends and (y) if after the Legend Removal
Date the Holder purchases (in an open market transaction or otherwise) shares of Common Stock to deliver in satisfaction of a sale
by the Holder of all or any portion of the number of shares of Common Stock, or a sale of a number of shares of Common Stock equal
to all or any portion of the number of shares of Common Stock, that the Holder anticipated receiving from the Company without any
restrictive legend, then an amount equal to the excess of the Holder’s total purchase price (including brokerage commissions
and other out-of-pocket expenses, if any) for the shares of Common Stock so purchased (including brokerage commissions and other
out-of-pocket expenses, if any) (the “Buy-In Price”) over the product of (I) such number of New Warrant Shares
that the Company was required to deliver to the Holder by the Legend Removal Date multiplied by (I) the lowest closing sale price
of the Common Stock on any Trading Day during the period commencing on the date of the delivery by the Holder to the Company of
the applicable New Warrant Shares (as the case may be) and ending on the date of such delivery and payment under this Section 4(a)(iv).

 

(v)       The
Cash Warrant Shares shall be issued free of legends.

 

(b)              
Disclosure of Transactions. The Company shall, within one business day of the Effective Date, issue a current report
on Form 8-K disclosing all material terms of the Transactions and including the form of this Agreement and the form of New Warrant
as exhibits thereto.

 

(c)               
Blue Sky. The Company shall make all filings and reports relating to the transactions contemplated hereby required
under applicable securities or “blue sky” laws of the states of the United States following the Closing Date, if any.

 

(d)              
Listing. The Company shall promptly secure the listing or designation for quotation (as applicable) of all of the
New Warrant Shares upon each trading market upon which the Common Stock is then listed or designated for quotation (as applicable)
(subject to official notice of issuance) and shall maintain such listing of all the New Warrant Shares from time to time issuable
under the terms of the New Warrants. The Company shall pay all fees and expenses in connection with satisfying its obligations
under this Section 4(d).

 

    	12

    

    

 

(e)               
Indemnification of Holder. Subject to the provisions of this Section 4(e), the Company will indemnify and hold the
Holder and its directors, officers, shareholders, members, managers, partners, employees and agents (and any other Persons with
a functionally equivalent role of a Person holding such titles notwithstanding a lack of such title or any other title), each Person
who controls the Holder (within the meaning of Section 15 of the Securities Act and Section 20 of the Exchange Act), and the directors,
officers, shareholders, agents, members, managers, partners or employees (and any other Persons with a functionally equivalent
role of a Person holding such titles notwithstanding a lack of such title or any other title) of such controlling persons (each,
a “Holder Party”) harmless from any and all losses, liabilities, obligations, claims, contingencies, damages,
costs and expenses, including all judgments, amounts paid in settlements, court costs and reasonable attorneys’ fees and
costs of investigation that any such Holder Party may suffer or incur as a result of or relating to (a) any breach of any of the
representations, warranties, covenants or agreements made by the Company in this Agreement, the other Transaction Documents, that
certain Warrant Amendment Agreement entered into on the date hereof between the Company and Holder (the “Warrant Amendment
Agreement”) or the Underwriting Agreement (b) any claim or action instituted against the Holder Parties in any capacity,
or any of them or their respective Affiliates, by any stockholder of the Company or other third party who is not an Affiliate of
such Holder Party, with respect to the Transactions or any of the other transactions contemplated by the Transaction Documents,
the Warrant Amendment Agreement or the Underwriting Agreement. In addition to the foregoing but without duplication, the Company
hereby agrees to indemnify each Holder Party from and against, all economic loss and internal and out-of-pocket costs, including
without limitation: (i) loss of “benefit of the bargain”, (ii) diminution in the fully-diluted ownership percentage
of the Company, and (iii) counsel fees, that may be incurred by Holder Party or its Affiliates in connection with any assertion
that Koninklijke DSM N.V. or any of its affiliates (collectively, “DSM”) have not consented to the transactions
contemplated by the Transaction Documents (the “DSM Consent”). If any action shall be brought against any Holder
Party in respect of which indemnity may be sought pursuant to this Agreement, or if an event occurs for which a Holder Party is
entitled to indemnity in connection with failure to obtain the DSM Consent, such Holder Party shall promptly notify the Company
in writing, and in the event of an action being brought, the Company shall have the right to assume the defense thereof with counsel
of its own choosing reasonably acceptable to the Holder Party. Any Holder Party shall have the right to employ separate counsel
in any such action and participate in the defense thereof, but the fees and expenses of such counsel shall be at the expense of
such Holder Party except to the extent that (i) the employment thereof has been specifically authorized by the Company in writing,
(ii) the Company has failed after a reasonable period of time to assume such defense and to employ counsel or (iii) in such action
there is, in the reasonable opinion of counsel, a material conflict on any material issue between the position of the Company and
the position of such Holder Party, in which case the Company shall be responsible for the reasonable fees and expenses of no more
than one such separate counsel. The Company will not be liable to any Holder Party under this Agreement (y) for any settlement
by a Holder Party effected without the Company’s prior written consent, which shall not be unreasonably withheld or delayed;
or (z) to the extent, but only to the extent, that a loss, claim, damage or liability is attributable to such Holder’s breach
of any of the representations, warranties, covenants or agreements made by such Holder in this Agreement or in the other Transaction
Documents. The indemnification required by this Section 4(e) shall be made by periodic payments of the amount thereof during the
course of the investigation or defense, as and when bills are received or are incurred. The indemnity agreements contained herein
shall be in addition to any cause of action or similar right of any Holder Party against the Company or others and any liabilities
the Company may be subject to pursuant to law. Notwithstanding the foregoing, a Holder Party shall not be entitled to indemnification
hereunder to the extent it is determined in a binding adjudication that the matters to be indemnified are the direct and proximate
result of: (i) breach by such Holder Party of its representations, warranties or covenants under the Transaction Documents, (ii)
violation by such Holder Party of state or federal securities laws, or (iii) the result of the fraud, gross negligence or willful
misconduct of such Holder Party. Upon any such finding, such Holder Party shall promptly return to the Company all indemnification
payments that had previously been made hereunder with respect to matters for which it is not entitled to indemnity.

 

    	13

    

    

 

(f)               
Furnishing of Information. Until the earliest of the time that (i) the Holder owns no New Securities or (ii) the
New Warrants have expired, the Company covenants to use reasonable best efforts to timely file (or obtain extensions in respect
thereof and file within the applicable grace period) all reports required to be filed by the Company after the Closing Date pursuant
to the Exchange Act even if the Company is not then subject to the reporting requirements of the Exchange Act.

 

(g)              
Reservation of Common Stock. As of the Closing Date, the Company has reserved and the Company shall continue to reserve
and keep available at all times, free of preemptive or similar rights, a sufficient number of shares of Common Stock for the purpose
of enabling the Company to issue all of the New Warrant Shares issuable upon exercise of the New Warrants.

 

(h)              
Exercise Procedures. Each of the form of Notice of Exercise included in the New Warrants set forth the totality of
the procedures required of the Holder in order to exercise the New Warrants. Without limiting the preceding sentences, no ink-original
Notice of Exercise shall be required, nor shall any medallion guarantee (or other type of guarantee or notarization) of any Notice
of Exercise form be required in order to exercise the New Warrants. No additional legal opinion, other information or instructions
shall be required of the Holder to exercise its New Warrants. The Company shall honor exercises of the New Warrants and shall deliver
the New Warrant Shares in accordance with the terms, conditions and time periods set forth in the Transaction Documents.

 

    	14

    

    

 

(i)                
Credit Against Cash Warrant Exercise Price.   Credit Against Cash Warrant Exercise Price. Each Holder shall
credit against payment of the exercise price of their respective Cash Warrants an aggregate amount of: (i) in the case of Vivo
Capital Fund VIII, L.P. $107,771 of amounts owed to such Holder by the Company; and (ii) in the case of Vivo Capital Surplus Fund
VIII, L.P., $14,882 of amounts owed to such Holder by the Company (collectively, the “Reimbursement Amounts”).
The parties acknowledge the existence of such indebtedness and agree that the Reimbursement Amounts will be applied to reduce the
cash amount that each such Holder would otherwise deliver to the Company for the “Initial Exercise” amount for such
Holder, as indicated on their respective signature pages to this Agreement.

 

 

5.                 
Miscellaneous.

 

(a)       Further
Assurances. Each party hereto shall promptly execute and deliver such further agreements and instruments, and take such further
actions, as the other party may reasonably request in order to carry out the purpose and intent of this Agreement.

 

(b)       Governing
Law; Jurisdiction; Jury Trial. This Agreement shall be governed by and construed and enforced in accordance with, and all questions
concerning the construction, validity, interpretation and performance of this Agreement shall be governed by, the internal laws
of the State of New York, without giving effect to any choice of law or conflict of law provision or rule (whether of the State
of New York or any other jurisdictions) that would cause the application of the laws of any jurisdictions other than the State
of New York. Each party hereby irrevocably waives personal service of process and consents to process being served in any such
suit, action or proceeding by mailing a copy thereof to the Company at the address for such notices to it under this Agreement
and agrees that such service shall constitute good and sufficient service of process and notice thereof. Each party hereby irrevocably
submits to the exclusive jurisdiction of the state and federal courts sitting in The City of New York, Borough of Manhattan, for
the adjudication of any dispute hereunder or in connection herewith or with any transaction contemplated hereby or discussed herein,
and hereby irrevocably waives, and agrees not to assert in any suit, action or proceeding, any claim that it is not personally
subject to the jurisdiction of any such court, that such suit, action or proceeding is brought in an inconvenient forum or that
the venue of such suit, action or proceeding is improper. Nothing contained herein shall be deemed to limit in any way any right
to serve process in any manner permitted by law. EACH PARTY HEREBY IRREVOCABLY WAIVES ANY RIGHT IT MAY HAVE TO, AND AGREES NOT
TO REQUEST, A JURY TRIAL FOR THE ADJUDICATION OF ANY DISPUTE HEREUNDER OR IN CONNECTION WITH OR ARISING OUT OF THIS AGREEMENT OR
ANY TRANSACTION CONTEMPLATED HEREBY.

 

(c)       Counterparts.
This Agreement may be executed in several counterparts, each of which shall be deemed an original, but all of which shall constitute
one and the same instrument.

 

(d)       Successors
and Assigns. Except as otherwise provided herein, the terms and conditions of this Agreement shall inure to the benefit of
and be binding upon the parties hereto and the respective successors and assigns of the parties. Nothing in this Agreement, express
or implied, is intended to confer upon any party, other than the parties hereto or their respective successors and assigns, any
rights, remedies, obligations or liabilities under or by reason of this Agreement, except as expressly provided in this Agreement.

 

    	15

    

    

 

(e)       Complete
Agreement. This Agreement, together with the Securities Purchase Agreement, the Underwriting Agreement, and the other Transaction
Documents (collectively, the “Exchange Documents”) represents the entire agreement and understandings between
the parties concerning the Transactions and the other matters described herein and therein and supersedes and replaces any and
all prior agreements and understandings solely with respect to the subject matter hereof and thereof. The parties acknowledge that
the Company and Holders have also entered into a Release Agreement dated August 17, 2018 that modifies the Exchange Documents in
some respects. Except as expressly set forth herein, nothing herein shall amend, modify or waive any term or condition of the other
Exchange Documents.

 

(f)       Expenses.
Except as specifically set forth herein, each party hereto shall bear its own costs and expenses, including, without limitation,
attorneys’ fees, incurred in connection with this Agreement and the transactions contemplated hereby.

 

(g)       Finder’s
Fees. Except as set forth in the Underwriting Agreement, each party represents that it neither is nor will be obligated for
any finder’s fee or commission in connection with this transaction. The Company shall indemnify and hold harmless the Holder
from any liability for any commission or compensation in the nature of a finder’s fee (and the reasonable costs and expenses
of defending against such liability or asserted liability) for which the Company or any of its officers, employees or representatives
is responsible.

 

(h)       Notices.
Any notices, consents, waivers or other communications required or permitted to be given under the terms of this Agreement must
be in writing and will be deemed to have been delivered: (i) upon receipt, when delivered personally; (ii) upon delivery, when
sent by facsimile (provided confirmation of transmission is mechanically or electronically generated and kept on file by the sending
party) or by electronic mail; or (iii) one Business Day after deposit with an overnight courier service, in each case properly
addressed to the party to receive the same. The addresses, facsimile numbers and e-mail addresses for such communications shall
be as set forth in the Securities Purchase Agreement or to such other address, facsimile number and/or e-mail address and/or to
the attention of such other Person as the recipient party has specified by written notice given to each other party five (5) days
prior to the effectiveness of such change. Written confirmation of receipt (A) given by the recipient of such notice, consent,
waiver or other communication, (B) mechanically or electronically generated by the sender’s facsimile machine or e-mail containing
the time, date, recipient facsimile number and an image of the first page of such transmission or (C) provided by an overnight
courier service shall be rebuttable evidence of personal service, receipt by facsimile or receipt from an overnight courier service
in accordance with clause (i), (ii) or (iii) above, respectively.

 

(i)       Amendments
and Waivers. Any term of this Agreement may be amended and the observance of any term of this Agreement may be waived (either
generally or in a particular instance and either retroactively or prospectively), only with the written consent of the Company
and the Holder.

 

    	16

    

    

 

(j)       Severability.
If one or more provisions of this Agreement are held to be unenforceable under applicable law, such provision shall be excluded
from this Agreement and the balance of the Agreement shall be interpreted as if such provision were so excluded and shall be enforceable
in accordance with its terms so long as this Agreement as so modified continues to express, without material change, the original
intentions of the parties as to the subject matter hereof and the prohibited nature, invalidity or unenforceability of the provision(s)
in question does not substantially impair the respective expectations or reciprocal obligations of the parties or the practical
realization of the benefits that would otherwise be conferred upon the parties. The parties will endeavor in good faith negotiations
to replace the prohibited, invalid or unenforceable provision(s) with a valid provision(s), the effect of which comes as close
as possible to that of the prohibited, invalid or unenforceable provision(s).

 

(k)       Interpretation.
Unless the context of this Agreement clearly requires otherwise, (i) references to the plural include the singular, the singular
the plural, the part the whole, (ii) references to any gender include all genders, (iii) “including” has the inclusive
meaning frequently identified with the phrase “but not limited to” and (iv) references to “hereunder” or
“herein” relate to this Agreement.

 

(l)       No
Third Party Beneficiaries. This Agreement is intended for the benefit of the parties hereto and their respective permitted
successors and assigns, and is not for the benefit of, nor may any provision hereof be enforced by, any other Person.

 

(m)       No
Strict Construction. The language used in this Agreement will be deemed to be the language chosen by the parties to express
their mutual intent, and no rules of strict construction will be applied against any party.

 

(n)       Independent
Nature of Holder’s Obligations and Rights. The obligations of the Holder under this Agreement are several and not joint
with the obligations of any Other Holder, and the Holder shall not be responsible in any way for the performance of the obligations
of any Other Holder under any Other Agreement. Nothing contained herein or in any Other Agreement, and no action taken by the Holder
pursuant hereto, shall be deemed to constitute the Holder and Other Holders as a partnership, an association, a joint venture or
any other kind of entity, or create a presumption that the Holder and Other Holders are in any way acting in concert or as a group
with respect to such obligations or the transactions contemplated by this Agreement or any Other Agreement and the Company acknowledges
that, to the best of its knowledge, the Holder and the Other Holders are not acting in concert or as a group with respect to such
obligations or the transactions contemplated by this Agreement or any Other Agreement. The Company and the Holder confirm that
the Holder has independently participated in the negotiation of the transactions contemplated hereby with the advice of its own
counsel and advisors. The Holder shall be entitled to independently protect and enforce its rights, including, without limitation,
the rights arising out of this Agreement, and it shall not be necessary for any Other Holder to be joined as an additional party
in any proceeding for such purpose

 

[signature page follows]

 

 

 

 

 

 

    	17

    

    

 

IN WITNESS WHEREOF, the
Holder and the Company have caused their respective signature page to this Agreement to be duly executed as of the date first written
above.

 

 

	 	 	AMYRIS, INC.
	 	 	 
	 	 	By: 	/s/ Kathleen Valiasek
	 	 	Name: 	Kathleen Valiasek
	 	 	Title:	Chief Financial Officer
	 	 	 

 

 

 

 

 

 

 

 

 

 

 

 

    

    

    

 

IN WITNESS WHEREOF, the
Holder and the Company have caused their respective signature page to this Agreement to be duly executed as of the date first written
above.

 

 

	 	 	HOLDER:
	 	 	 
	 	 	VIVO CAPITAL SURPLUS FUND VIII, L.P.
	 	 	 
	 	 	 
	 	 	By:  	/s/ Frank Kung
	 	 	Name:	Frank Kung
	 	 	Title: 	Managing Member of Vivo Capital VIII, LLC, General Partner
	 	 	 	 
	 	 	Address for delivery of New Warrants:
	 	 	 
	 	 	505 Hamilton Avenue, Suite 207, Palo Alto, CA
94301
	 	 	 
	 	 	 
	 	 	 
	 	 	Aggregate Number of Cash Warrant Shares Issuable Upon Exercise of the Cash Warrant
of the Holder*:
	 	 	 
	 	 	676,448
	 	 	 
	 	 	Aggregate Cash Warrant Share Exercise Amount*:
	 	 	 
	 	 	For Initial Exercise:	 478,571
	 	 	For Second Exercise:	Up to 197,877
	 	 	 
	 	 	Aggregate Exercise Price of Cash Warrant Share Exercise Amount
	 	 	 
	 	 	For Initial Exercise:	$2,105,712.40
	 	 	For Second Exercise:	Up to $870,658.80
	 	 	 
	 	 	*Disregarding any limitations on exercise related thereto.
	 	 	 
	 	 	_______Check here if Holder is electing to have the 180
day lock-up provisions in Annex I attached hereto apply to Holder’s Cash Warrant Share Exercise Amount of Cash Warrant
Shares to permit a cashless exercise of the Cash Warrant

 

 

 

    

    

    

 

Annex I

 

Required Lock-Up Provisions for Cashless Exercise of Cash Warrant

 

In consideration of the Company granting the
Holder the right to cashless exercise, in whole or in part, the Cash Warrant (in lieu of the required cash exercise pursuant to
the Notice of Exercise) and still participate in the other Transactions and for other good and valuable consideration, receipt
of which is hereby acknowledged, the Holder will not, during the period beginning on the date hereof and continuing to and including
the date 180 days after the date hereof, (1) offer, pledge, announce the intention to sell, sell, contract to sell, sell any option
or contract to purchase, purchase any option or contract to sell, grant any option, right or warrant to purchase, or otherwise
transfer or dispose of, directly or indirectly, any Cash Warrant Shares, or (2) enter into any swap or other agreement that transfers,
in whole or in part, any of the economic consequences of ownership of any Cash Warrant Shares, whether any such transaction described
in clause (1) or (2) above is to be settled by delivery of any Cash Warrant Shares, in cash or otherwise. The foregoing restrictions
are expressly agreed to preclude the Holder from engaging in any hedging or other transaction which is designed to or reasonably
expected to lead to or result in a sale or disposition of any Cash Warrant Shares even if such securities would be disposed of
by someone other than the Holder.

 

Notwithstanding the foregoing, the restrictions
set forth in clause (1) and (2) above shall not apply to transfers (a) as a bona fide gift or gifts, provided that the donee or
donees thereof agree to be bound in writing by the restrictions set forth herein or (b) to any trust for the direct or indirect
benefit of the Holder or the immediate family of the Holder, provided that the trustee of the trust agrees to be bound in writing
by the restrictions set forth herein, and provided further that any such transfer shall not involve a disposition for value. For
purposes of this Annex I, “immediate family” shall mean any relationship by blood, marriage or adoption, not
more remote than first cousin.

 

 

 

 

 

    

    

    

 

 

Exhibit A

 

 

 

 

 

 

 

 

 

 

 

 

 

 

    

    

    

 

NEITHER THIS SECURITY NOR THE SECURITIES INTO WHICH THIS SECURITY
IS EXERCISABLE HAS BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE
UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY,
MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR PURSUANT TO AN AVAILABLE
EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT AND IN ACCORDANCE WITH
APPLICABLE STATE SECURITIES LAWS. THIS SECURITY AND THE SECURITIES ISSUABLE UPON EXERCISE OF THIS SECURITY MAY BE PLEDGED IN CONNECTION
WITH A BONA FIDE MARGIN ACCOUNT WITH A REGISTERED BROKER-DEALER OR OTHER LOAN WITH A FINANCIAL INSTITUTION THAT IS AN “ACCREDITED
INVESTOR” AS DEFINED IN RULE 501(a) UNDER THE SECURITIES ACT OR OTHER LOAN SECURED BY SUCH SECURITIES.

 

COMMON STOCK PURCHASE WARRANT

 

AMYRIS, INC. 

 

	Warrant Shares: _______________1	Issue Date: August 17, 2018

 

 

THIS COMMON STOCK PURCHASE WARRANT (the “Warrant”)
certifies that, for value received, Vivo Surplus Fund VIII, L.P. or its assigns (the “Holder”) is entitled,
upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the
open of business on the six month anniversary of the date hereof (the “Initial Exercise Date”) and on or prior
to the close of business on the fifteen month anniversary of the Initial Exercise Date (the “Termination Date”)
but not thereafter, to subscribe for and purchase from Amyris, Inc., a Delaware corporation (the “Company”),
up to _________ shares (as subject to adjustment hereunder, the “Warrant Shares”) of Common Stock. The purchase
price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b).

 

Section 1.Definitions.
Capitalized terms used and not otherwise defined herein shall have the meanings set forth in that certain Warrant Exercise Agreement
(the “Warrant Exercise Agreement”), dated August 17, 2018, among the Company and the Holder, as such definitions
are in effect on August 17, 2018.

 

Section 2.Exercise.

 

a)                 
Exercise of Warrant. Exercise of the purchase rights represented by this Warrant may be made, in whole or in part,
at any time or times on or after the Initial Exercise Date and on or before the Termination Date by delivery to the Company of
a duly executed facsimile copy or PDF copy submitted by electronic (or e-mail attachment) of the Notice of Exercise in the form
annexed hereto (“Notice of Exercise”). Within two (2) Trading Days following the date of exercise as aforesaid,
the Holder shall deliver the aggregate Exercise Price for the shares specified in the applicable Notice of Exercise by wire transfer
or cashier’s check drawn on a United States bank unless the cashless exercise procedure specified in Section 2(c) below is
specified in the applicable Notice of Exercise. No ink-original Notice of Exercise shall be required, nor shall any medallion guarantee
(or other type of guarantee or notarization) of any Notice of Exercise form be required. Notwithstanding anything herein to the
contrary, the Holder shall not be required to physically surrender this Warrant to the Company until the Holder has purchased all
of the Warrant Shares available hereunder and the Warrant has been exercised in full, in which case, the Holder shall surrender
this Warrant to the Company for cancellation within three (3) Trading Days of the date the final Notice of Exercise is delivered
to the Company. Partial exercises of this Warrant resulting in purchases of a portion of the total number of Warrant Shares available
hereunder shall have the effect of lowering the outstanding number of Warrant Shares purchasable hereunder in an amount equal to
the applicable number of Warrant Shares purchased. The Company shall maintain records showing the number of Warrant Shares purchased
and the date of such purchases. The Company shall deliver any objection to any Notice of Exercise within one (1) Business Day of
receipt of such notice. The Holder and any assignee, by acceptance of this Warrant, acknowledge and agree that, by reason of
the provisions of this paragraph, following the purchase of a portion of the Warrant Shares hereunder, the number of Warrant Shares
available for purchase hereunder at any given time may be less than the amount stated on the face hereof.

 

 

________________________

1 The New Warrant
issued on the Initial Exercise Date will be for 619,749 shares. The New Warrant issued on the Second Exercise Date will be for
up to 256,251 shares.

 

    	1

    

    

 

b)                 
Exercise Price. The exercise price per share of the Common Stock under this Warrant shall be $7.52, subject to adjustment
hereunder (the “Exercise Price”).

 

c)                 
Cashless Exercise. Notwithstanding anything contained herein to the contrary, if a registration statement covering
the resale of the Warrant Shares subject to the applicable Notice of Exercise is not available for the resale of such Warrant Shares,
at any time after the six month anniversary of the Initial Exercise Date, this Warrant may be exercised, in whole or in part, at
any time or times on or after the Initial Exercise Date and on or before the Termination Date at the election of the Holder (in
such Holder’s sole discretion) by means of a “cashless exercise” in which the Holder shall be entitled to receive
a number of Warrant Shares equal to the quotient obtained by dividing ((A-B) * (X)) by (A), where:

 

(A) = as applicable: (i) the VWAP on
the Trading Day immediately preceding the date of the applicable Notice of Exercise if such Notice of Exercise is (1) both executed
and delivered pursuant to Section 2(a) hereof on a day that is not a Trading Day or (2) both executed and delivered pursuant to
Section 2(a) hereof on a Trading Day prior to the opening of “regular trading hours” (as defined in Rule 600(b)(64)
of Regulation NMS promulgated under the federal securities laws) on such Trading Day, (ii) at the option of the Holder, either
(y) the VWAP on the Trading Day immediately preceding the date of the applicable Notice of Exercise or (z) the Bid Price of the
Common Stock on the principal Trading Market as reported by Bloomberg L.P. as of the time of the Holder’s execution of the
applicable Notice of Exercise if such Notice of Exercise is executed during “regular trading hours” on a Trading Day
and is delivered within two (2) hours thereafter (including until two (2) hours after the close of “regular trading hours”
on a Trading Day) pursuant to Section 2(a) hereof or (iii) the VWAP on the date of the applicable Notice of Exercise if the date
of such Notice of Exercise is a Trading Day and such Notice of Exercise is both executed and delivered pursuant to Section 2(a)
hereof after the close of “regular trading hours” on such Trading Day;

 

    	2

    

    

 

(B) = the Exercise Price of this
Warrant, as adjusted hereunder; and

 

(X) = the number of Warrant Shares
that would be issuable upon exercise of this Warrant in accordance with the terms of this Warrant if such exercise were by means
of a cash exercise rather than a cashless exercise.

 

If
Warrant Shares are issued in such a cashless exercise, the parties acknowledge and agree that in accordance with Section 3(a)(9)
of the Securities Act, the Warrant Shares shall take on the characteristics of the Warrants being exercised, and the holding period
of the Warrant Shares being issued may be tacked on to the holding period of this Warrant.  The Company agrees not to
take any position contrary to this Section 2(c).

 

“Bid Price” means,
for any date, the price determined by the first of the following clauses that applies: (a) if the Common Stock is then listed or
quoted on a Trading Market, the bid price of the Common Stock for the time in question (or the nearest preceding date) on the Trading
Market on which the Common Stock is then listed or quoted as reported by Bloomberg L.P. (based on a Trading Day from 9:30 a.m.
(New York City time) to 4:02 p.m. (New York City time)), (b)  if OTCQB or OTCQX is not a Trading Market, the volume weighted
average price of the Common Stock for such date (or the nearest preceding date) on OTCQB or OTCQX as applicable, (c) if the Common
Stock is not then listed or quoted for trading on OTCQB or OTCQX and if prices for the Common Stock are then reported in the “Pink
Sheets” published by OTC Markets Group, Inc. (or a similar organization or agency succeeding to its functions of reporting
prices), the most recent bid price per share of the Common Stock so reported, or (d) in all other cases, the fair market value
of a share of Common Stock as determined by an independent appraiser selected in good faith by the Holder and reasonably acceptable
to the Company, the fees and expenses of which shall be paid by the Company.

 

“VWAP” means, for
any date, the price determined by the first of the following clauses that applies: (a) if the Common Stock is then listed or quoted
on a Trading Market, the daily volume weighted average price of the Common Stock for such date (or the nearest preceding date)
on the Trading Market on which the Common Stock is then listed or quoted as reported by Bloomberg L.P. (based on a Trading Day
from 9:30 a.m. (New York City time) to 4:02 p.m. (New York City time)), (b)  if OTCQB or OTCQX is not a Trading Market, the
volume weighted average price of the Common Stock for such date (or the nearest preceding date) on OTCQB or OTCQX as applicable,
(c) if the Common Stock is not then listed or quoted for trading on OTCQB or OTCQX and if prices for the Common Stock are then
reported in the “Pink Sheets” published by OTC Markets Group, Inc. (or a similar organization or agency succeeding
to its functions of reporting prices), the most recent bid price per share of the Common Stock so reported, or (d) in all
other cases, the fair market value of a share of Common Stock as determined by an independent appraiser selected in good faith
by the Holder and reasonably acceptable to the Company, the fees and expenses of which shall be paid by the Company.

 

    	3

    

    

 

Notwithstanding anything herein to
the contrary, on the Termination Date, if a registration statement covering the resale of the Warrant Shares is not available for
the resale of the Warrant Shares, this Warrant shall be automatically exercised via cashless exercise pursuant to this Section
2(c).

 

d)       
Mechanics of Exercise.

 

		i.	Delivery of Warrant Shares Upon Exercise. Warrant Shares purchased hereunder shall be transmitted
by the Transfer Agent to the Holder by crediting the account of the Holder’s or its designee’s balance account with
The Depository Trust Company through its Deposit or Withdrawal at Custodian system (“DWAC”) if the Company is
then a participant in such system and either (A) there is an effective registration statement permitting the issuance of the Warrant
Shares to or resale of the Warrant Shares by the Holder or (B) the Warrant Shares are eligible for resale by the Holder without
volume or manner-of-sale limitations pursuant to Rule 144, and otherwise by physical delivery of a certificate, registered in the
Company’s share register in the name of the Holder or its designee, for the number of Warrant Shares to which the Holder
is entitled pursuant to such exercise to the address specified by the Holder in the Notice of Exercise by the date that is the
earlier of (i) two (2) Trading Days after the delivery to the Company of the Notice of Exercise and (ii) one (1) Trading Day after
delivery of the aggregate Exercise Price to the Company (such date, the “Warrant Share Delivery Date”). Upon
delivery of the Notice of Exercise, the Holder shall be deemed for all corporate purposes to have become the holder of record of
the Warrant Shares with respect to which this Warrant has been exercised, irrespective of the date of delivery of the Warrant Shares,
provided that payment of the aggregate Exercise Price (other than in the case of a cashless exercise) is received within two (2)
Trading following delivery of the Notice of Exercise. If the Company fails for any reason to deliver to the Holder the Warrant
Shares subject to a Notice of Exercise by the Warrant Share Delivery Date, the Company shall pay to the Holder, in cash, as liquidated
damages and not as a penalty, for each $1,000 of Warrant Shares subject to such exercise (based on the VWAP of the Common Stock
on the date of the applicable Notice of Exercise), $10 per Trading Day (increasing to $20 per Trading Day on the fifth Trading
Day after such liquidated damages begin to accrue) for each Trading Day commencing one Trading Day after such Warrant Share Delivery
Date until such Warrant Shares are delivered or Holder rescinds such exercise. The Company agrees to maintain a transfer agent
that is a participant in the FAST program so long as this Warrant remains outstanding and exercisable.

 

    	4

    

    

 

ii.                     Delivery
of New Warrants Upon Exercise. If this Warrant shall have been exercised in part, the Company shall, at the request of a Holder
and upon surrender of this Warrant certificate, at the time of delivery of the Warrant Shares, deliver to the Holder a new Warrant
evidencing the rights of the Holder to purchase the unpurchased Warrant Shares called for by this Warrant, which new Warrant shall
in all other respects be identical with this Warrant.

 

iii.                  Rescission
Rights. If the Company fails to cause the Transfer Agent to transmit to the Holder the Warrant Shares pursuant to Section 2(d)(i)
by the Warrant Share Delivery Date, then the Holder will have the right to rescind such exercise.

 

iv.                  Compensation
for Buy-In on Failure to Timely Deliver Warrant Shares Upon Exercise. In addition to any other rights available to the Holder,
if the Company fails to cause the Transfer Agent to transmit to the Holder the Warrant Shares in accordance with the provisions
of Section 2(d)(i) above pursuant to an exercise on or before the Warrant Share Delivery Date, and if after such date the Holder
is required by its broker to purchase (in an open market transaction or otherwise) or the Holder’s brokerage firm otherwise
purchases, shares of Common Stock to deliver in satisfaction of a sale by the Holder of the Warrant Shares which the Holder anticipated
receiving upon such exercise (a “Buy-In”), then the Company shall (A) pay in cash to the Holder the amount,
if any, by which (x) the Holder’s total purchase price (including brokerage commissions, if any) for the shares of Common
Stock so purchased exceeds (y) the amount obtained by multiplying (1) the number of Warrant Shares that the Company was required
to deliver to the Holder in connection with the exercise at issue times (2) the price at which the sell order giving rise to such
purchase obligation was executed, and (B) at the option of the Holder, either reinstate the portion of the Warrant and equivalent
number of Warrant Shares for which such exercise was not honored (in which case such exercise shall be deemed rescinded) or deliver
to the Holder the number of shares of Common Stock that would have been issued had the Company timely complied with its exercise
and delivery obligations hereunder. For example, if the Holder purchases Common Stock having a total purchase price of $11,000
to cover a Buy-In with respect to an attempted exercise of shares of Common Stock with an aggregate sale price giving rise to such
purchase obligation of $10,000, under clause (A) of the immediately preceding sentence the Company shall be required to pay the
Holder $1,000. The Holder shall provide the Company written notice indicating the amounts payable to the Holder in respect of the
Buy-In and, upon request of the Company, evidence of the amount of such loss. Nothing herein shall limit a Holder’s right
to pursue any other remedies available to it hereunder, at law or in equity including, without limitation, a decree of specific
performance and/or injunctive relief with respect to the Company’s failure to timely deliver shares of Common Stock upon
exercise of the Warrant as required pursuant to the terms hereof.

 

    	5

    

    

 

v.                  No Fractional
Shares or Scrip. No fractional shares or scrip representing fractional shares shall be issued upon the exercise of this Warrant.
As to any fraction of a share which the Holder would otherwise be entitled to purchase upon such exercise, the Company shall, at
its election, either pay a cash adjustment in respect of such final fraction in an amount equal to such fraction multiplied by
the Exercise Price or round up to the next whole share.

 

vi.                  Charges, Taxes
and Expenses. Issuance of Warrant Shares shall be made without charge to the Holder for any issue or transfer tax or other
incidental expense in respect of the issuance of such Warrant Shares, all of which taxes and expenses shall be paid by the Company,
and such Warrant Shares shall be issued in the name of the Holder or in such name or names as may be directed by the Holder; provided,
however, that in the event that Warrant Shares are to be issued in a name other than the name of the Holder, this Warrant
when surrendered for exercise shall be accompanied by the Assignment Form attached hereto duly executed by the Holder and the Company
may require, as a condition thereto, the payment of a sum sufficient to reimburse it for any transfer tax incidental thereto. The
Company shall pay all Transfer Agent fees required for same-day processing of any Notice of Exercise and all fees to the Depository
Trust Company (or another established clearing corporation performing similar functions) required for same-day electronic delivery
of the Warrant Shares.

 

vii.                  Closing of
Books. The Company will not close its stockholder books or records in any manner which prevents the timely exercise of this
Warrant, pursuant to the terms hereof.

 

    	6

    

    

 

e)        
Holder’s Exercise Limitations. Notwithstanding anything to the contrary contained herein, the Company shall
not effect any exercise of this Warrant, and a Holder shall not have the right to exercise any portion of this Warrant, pursuant
to Section 2 or otherwise, to the extent that after giving effect to such issuance after exercise as set forth on the applicable
Notice of Exercise, the Holder (together with the Holder’s Affiliates, and any other Persons acting as a group together with
the Holder or any of the Holder’s Affiliates (such Persons, “Attribution Parties”)), would beneficially
own in excess of the Beneficial Ownership Limitation (as defined below).  For purposes of the foregoing sentence, the number
of shares of Common Stock beneficially owned by the Holder and its Affiliates and Attribution Parties shall include the number
of shares of Common Stock issuable upon exercise of this Warrant with respect to which such determination is being made, but shall
exclude the number of shares of Common Stock which would be issuable upon (i) exercise of the remaining, nonexercised portion of
this Warrant beneficially owned by the Holder or any of its Affiliates or Attribution Parties and (ii) exercise or conversion of
the unexercised or nonconverted portion of any other securities of the Company (including, without limitation, any other Common
Stock Equivalents (as defined below)) subject to a limitation on conversion or exercise analogous to the limitation contained herein
beneficially owned by the Holder or any of its Affiliates or Attribution Parties.  Except as set forth in the preceding sentence,
for purposes of this Section 2(e), beneficial ownership shall be calculated in accordance with Section 13(d) of the Exchange Act
and the rules and regulations promulgated thereunder, it being acknowledged by the Holder that the Company is not representing
to the Holder that such calculation is in compliance with Section 13(d) of the Exchange Act and the Holder is solely responsible
for any schedules required to be filed in accordance therewith. To the extent that the limitation contained in this Section 2(e)
applies, the determination of whether this Warrant is exercisable (in relation to other securities owned by the Holder together
with any Affiliates and Attribution Parties) and of which portion of this Warrant is exercisable shall be in the sole discretion
of the Holder, and the submission of a Notice of Exercise shall be deemed to be the Holder’s determination of whether this
Warrant is exercisable (in relation to other securities owned by the Holder together with any Affiliates and Attribution Parties)
and of which portion of this Warrant is exercisable, in each case subject to the Beneficial Ownership Limitation, and the Company
shall have no obligation to verify or confirm the accuracy of such determination. In addition, a determination as to any group
status as contemplated above shall be determined in accordance with Section 13(d) of the Exchange Act and the rules and regulations
promulgated thereunder. For purposes of this Section 2(e), in determining the number of outstanding shares of Common Stock, a Holder
may rely on the number of outstanding shares of Common Stock as reflected in (A) the Company’s most recent periodic or annual
report filed with the Commission, as the case may be, (B) a more recent public announcement by the Company or (C) a more recent
written notice by the Company or the Transfer Agent setting forth the number of shares of Common Stock outstanding.  Upon
the written or oral request of a Holder, the Company shall within two Trading Days confirm orally and in writing to the Holder
the number of shares of Common Stock then outstanding.  In any case, the number of outstanding shares of Common Stock shall
be determined after giving effect to the conversion or exercise of securities of the Company, including this Warrant, by the Holder
or its Affiliates or Attribution Parties since the date as of which such number of outstanding shares of Common Stock was reported.
The “Beneficial Ownership Limitation” shall be 9.99% of the number of shares of the Common Stock outstanding
immediately after giving effect to the issuance of shares of Common Stock issuable upon exercise of this Warrant. The Holder, upon
notice to the Company, may waive the Beneficial Ownership Limitation provisions of this Section 2(e), provided that such waiver
(i) will not be effective until the 61st day after such notice is delivered to the Company, and (ii) will not be
effective to the extent such waiver would require the prior approval of the Company’s stockholders, unless such approval
has been obtained. If such stockholder approval is required and has not been obtained, the Company shall use its commercially reasonable
efforts to timely obtain such stockholder approval. The provisions of this paragraph shall be construed and implemented in a manner
otherwise than in strict conformity with the terms of this Section 2(e) to correct this paragraph (or any portion hereof) which
may be defective or inconsistent with the intended Beneficial Ownership Limitation herein contained or to make changes or supplements
necessary or desirable to properly give effect to such limitation. The limitations contained in this paragraph shall apply to a
successor holder of this Warrant. “Common Stock Equivalents” means any securities of the Company or its subsidiaries
which would entitle the holder thereof to acquire at any time Common Stock, including, without limitation, any debt, preferred
stock, right, option, warrant or other instrument that is at any time convertible into, or exercisable or exchangeable for, or
otherwise entitles the holder thereof to receive, Common Stock.

 

    	7

    

    

 

Section 3.Certain
Adjustments.

 

a)     
Stock Dividends and Splits. If the Company, at any time while this Warrant is outstanding: (i) pays a stock dividend
or otherwise makes a distribution or distributions on shares of its Common Stock or any other equity or equity equivalent securities
payable in shares of Common Stock (which, for avoidance of doubt, shall not include any shares of Common Stock issued by the Company
upon exercise of this Warrant), (ii) subdivides outstanding shares of Common Stock into a larger number of shares, (iii) combines
(including by way of reverse stock split) outstanding shares of Common Stock into a smaller number of shares or (iv) issues by
reclassification of shares of the Common Stock any shares of capital stock of the Company, then in each case the Exercise Price
shall be multiplied by a fraction of which the numerator shall be the number of shares of Common Stock (excluding treasury shares,
if any) outstanding immediately before such event and of which the denominator shall be the number of shares of Common Stock outstanding
immediately after such event, and the number of shares issuable upon exercise of this Warrant shall be proportionately adjusted
such that the aggregate Exercise Price of this Warrant shall remain unchanged. Any adjustment made pursuant to this Section 3(a)
shall become effective immediately after the record date for the determination of stockholders entitled to receive such dividend
or distribution and shall become effective immediately after the effective date in the case of a subdivision, combination or re-classification.

 

b)     
[INTENTIONALLY OMITTED]

 

		c)	Subsequent Rights Offerings. In addition to any adjustments pursuant to Section 3(a) above,
if at any time after the Original Issue Date the Company grants, issues or sells any Common Stock Equivalents or rights to purchase
stock, warrants, securities or other property pro rata to the record holders of any class of shares of Common Stock (the “Purchase
Rights”), then each Holder will be entitled to acquire, upon the terms applicable to such Purchase Rights, the aggregate
Purchase Rights which the Holder could have acquired if the Holder had held the number of shares of Common Stock acquirable upon
complete exercise of this Warrant (without regard to any limitations on exercise hereof, including without limitation, the Beneficial
Ownership Limitation) immediately before the date on which a record is taken for the grant, issuance or sale of such Purchase Rights,
or, if no such record is taken, the date as of which the record holders of shares of Common Stock are to be determined for the
grant, issue or sale of such Purchase Rights (provided, however, to the extent that the Holder’s right to participate in
any such Purchase Right would result in the Holder exceeding the Beneficial Ownership Limitation and the Beneficial Ownership Limitation
is not waived by the Holder, then the Holder shall not be entitled to participate in such Purchase Right to such extent (or beneficial
ownership of such shares of Common Stock as a result of such Purchase Right to such extent) and such Purchase Right to such extent
shall be held in abeyance for the Holder until such time, if ever, as its right thereto would not result in the Holder exceeding
the Beneficial Ownership Limitation).

 

    	8

    

    

 

d)    
Pro Rata Distributions. During such time as this Warrant is outstanding, if the Company shall declare or make any
dividend or other distribution of its assets (or rights to acquire its assets) to holders of shares of Common Stock, by way of
return of capital or otherwise (including, without limitation, any distribution of cash, stock or other securities, property or
options by way of a dividend, spin off, reclassification, corporate rearrangement, scheme of arrangement or other similar transaction,
but excluding any dividend that results in adjustment to the Conversion Price pursuant to Section 3(a) above) (a “Distribution”),
at any time after the issuance of this Warrant, then, in each such case, the Holder shall be entitled to participate in such Distribution
to the same extent that the Holder would have participated therein if the Holder had held the number of shares of Common Stock
acquirable upon complete exercise of this Warrant (without regard to any limitations on exercise hereof, including without limitation,
the Beneficial Ownership Limitation) immediately before the date of which a record is taken for such Distribution, or, if no such
record is taken, the date as of which the record holders of shares of Common Stock are to be determined for the participation in
such Distribution (provided, however, to the extent that the Holder's right to participate in any such Distribution
would result in the Holder exceeding the Beneficial Ownership Limitation and the Beneficial Ownership Limitation is not waived
by the Holder, then the Holder shall not be entitled to participate in such Distribution to such extent (or in the beneficial ownership
of any shares of Common Stock as a result of such Distribution to such extent) and the portion of such Distribution shall be held
in abeyance for the benefit of the Holder until such time, if ever, as its right thereto would not result in the Holder exceeding
the Beneficial Ownership Limitation).

 

e)     
Fundamental Transaction. If, at any time while this Warrant is outstanding, (i) the Company, directly or indirectly,
in one or more related transactions effects any merger or consolidation of the Company with or into another Person, (ii) the Company,
directly or indirectly, effects any sale, lease, license, assignment, transfer, conveyance or other disposition of all or substantially
all of its assets in one or a series of related transactions, (iii) any, direct or indirect, purchase offer, tender offer or exchange
offer (whether by the Company or another Person) is completed pursuant to which holders of Common Stock are permitted to sell,
tender or exchange their shares for other securities, cash or property and has been accepted by the holders of 50% or more of the
outstanding Common Stock, (iv) the Company, directly or indirectly, in one or more related transactions effects any reclassification,
reorganization or recapitalization of the Common Stock or any compulsory share exchange pursuant to which the Common Stock is effectively
converted into or exchanged for other securities, cash or property, or (v) the Company, directly or indirectly, in one or more
related transactions consummates a stock or share purchase agreement or other business combination (including, without limitation,
a reorganization, recapitalization, spin-off or scheme of arrangement) with another Person or group of Persons whereby such other
Person or group acquires more than 50% of the outstanding shares of Common Stock (not including any shares of Common Stock held
by the other Person or other Persons making or party to, or associated or affiliated with the other Persons making or party to,
such stock or share purchase agreement or other business combination) (each a “Fundamental Transaction”), then,
the Holder shall have the right to receive, for each Warrant Share that would have been issuable upon such exercise immediately
prior to the occurrence of such Fundamental Transaction (as if the exercise of the Warrant occurred immediately prior to the occurrence
of such Fundamental Transaction), at the option of the Holder (without regard to any limitation in Section 2(e) on the exercise
of this Warrant), the number of shares of common stock of the successor or acquiring corporation or shares of Common Stock of the
Company, if it is the surviving corporation, and any additional consideration (the “Alternate Consideration”)
receivable as a result of such Fundamental Transaction by a holder of the number of shares of Common Stock for which this Warrant
is exercisable immediately prior to such Fundamental Transaction (without regard to any limitation in Section 2(e) on the exercise
of this Warrant). For purposes of any such exercise, the determination of the Exercise Price shall be appropriately adjusted to
apply to such Alternate Consideration based on the amount of Alternate Consideration issuable in respect of one share of Common
Stock in such Fundamental Transaction, and the Company shall apportion the Exercise Price among the Alternate Consideration in
a reasonable manner reflecting the relative value of any different components of the Alternate Consideration. If holders of Common
Stock are given any choice as to the securities, cash or property to be received in a Fundamental Transaction, then the Holder
shall be given the same choice as to the Alternate Consideration it receives upon any exercise of this Warrant following such Fundamental
Transaction.

 

    	9

    

    

 

f)      
Calculations. All calculations under this Section 3 shall be made to the nearest cent or the nearest 1/100th of a
share, as the case may be. For purposes of this Section 3, the number of shares of Common Stock deemed to be issued and outstanding
as of a given date shall be the sum of the number of shares of Common Stock (excluding treasury shares, if any) issued and outstanding.

 

g)     
Notice to Holder.

 

i.      Adjustment to Exercise Price. Whenever the Exercise Price is adjusted pursuant to
any provision of this Section 3, the Company shall within two (2) Trading Days deliver to the Holder by facsimile or email a notice
setting forth the Exercise Price after such adjustment and any resulting adjustment to the number of Warrant Shares and setting
forth a brief statement of the facts requiring such adjustment.

 

    	10

    

    

 

ii.      Notice to Allow Exercise by Holder. If (A) the Company shall declare a dividend
(or any other distribution in whatever form) on the Common Stock, (B) the Company shall declare a special nonrecurring cash dividend
on or a redemption of the Common Stock, (C) the Company shall authorize the granting to all holders of the Common Stock rights
or warrants to subscribe for or purchase any shares of capital stock of any class or of any rights, (D) the approval of any stockholders
of the Company shall be required in connection with any reclassification of the Common Stock, any consolidation or merger to which
the Company is a party, any sale or transfer of all or substantially all of the assets of the Company, or any compulsory share
exchange whereby the Common Stock is converted into other securities, cash or property, or (E) the Company shall authorize the
voluntary or involuntary dissolution, liquidation or winding up of the affairs of the Company, then, in each case, the Company
shall cause to be delivered by facsimile or email to the Holder at its last facsimile number or email address as it shall appear
upon the Warrant Register of the Company, at least 20 calendar days prior to the applicable record or effective date hereinafter
specified, a notice stating (x) the date on which a record is to be taken for the purpose of such dividend, distribution, redemption,
rights or warrants, or if a record is not to be taken, the date as of which the holders of the Common Stock of record to be entitled
to such dividend, distributions, redemption, rights or warrants are to be determined or (y) the date on which such reclassification,
consolidation, merger, sale, transfer or share exchange is expected to become effective or close, and the date as of which it is
expected that holders of the Common Stock of record shall be entitled to exchange their shares of the Common Stock for securities,
cash or other property deliverable upon such reclassification, consolidation, merger, sale, transfer or share exchange; provided
that the failure to deliver such notice or any defect therein or in the delivery thereof shall not affect the validity of the corporate
action required to be specified in such notice. To the extent that any notice provided in this Warrant constitutes, or contains,
material, non-public information regarding the Company or any of the Subsidiaries, the Company shall simultaneously file such notice
with the Commission pursuant to a Current Report on Form 8-K. The Holder shall remain entitled to exercise this Warrant during
the period commencing on the date of such notice to the effective date of the event triggering such notice except as may otherwise
be expressly set forth herein.

 

Section 4.Transfer
of Warrant.

 

a)     
Transferability. Subject to compliance with any applicable securities laws and the conditions set forth in Section
4(d) hereof and to the provisions of Section 4(a) of the Warrant Exercise Agreement, this Warrant and all rights hereunder are
transferable, in whole or in part, upon surrender of this Warrant at the principal office of the Company or its designated agent,
together with a written assignment of this Warrant substantially in the form attached hereto duly executed by the Holder or its
agent or attorney and funds sufficient to pay any transfer taxes payable upon the making of such transfer. Upon such surrender
and, if required, such payment, the Company shall execute and deliver a new Warrant or Warrants in the name of the assignee or
assignees, as applicable, and in the denomination or denominations specified in such instrument of assignment, and shall issue
to the assignor a new Warrant evidencing the portion of this Warrant not so assigned, and this Warrant shall promptly be cancelled.
Notwithstanding anything herein to the contrary, the Holder shall not be required to physically surrender this Warrant to the Company
unless the Holder has assigned this Warrant in full, in which case, the Holder shall surrender this Warrant to the Company within
three (3) Trading Days of the date the Holder delivers an assignment form to the Company assigning this Warrant full. The Warrant,
if properly assigned in accordance herewith, may be exercised by a new holder for the purchase of Warrant Shares without having
a new Warrant issued.

 

    	11

    

    

 

b)     
New Warrants. This Warrant may be divided or combined with other Warrants upon presentation hereof at the aforesaid
office of the Company, together with a written notice specifying the names and denominations in which new Warrants are to be issued,
signed by the Holder or its agent or attorney. Subject to compliance with Section 4(a), as to any transfer which may be involved
in such division or combination, the Company shall execute and deliver a new Warrant or Warrants in exchange for the Warrant or
Warrants to be divided or combined in accordance with such notice. All Warrants issued on transfers or exchanges shall be dated
the original issue date and shall be identical with this Warrant except as to the number of Warrant Shares issuable pursuant thereto.

 

c)     
Warrant Register. The Company shall register this Warrant, upon records to be maintained by the Company for that
purpose (the “Warrant Register”), in the name of the record Holder hereof from time to time. The Company may
deem and treat the registered Holder of this Warrant as the absolute owner hereof for the purpose of any exercise hereof or any
distribution to the Holder, and for all other purposes, absent actual notice to the contrary.

 

d)    
Transfer Restrictions. If, at the time of the surrender of this Warrant in connection with any transfer of this Warrant,
the transfer of this Warrant shall not be either (i) registered pursuant to an effective registration statement under the Securities
Act and under applicable state securities or blue sky laws or (ii) eligible for resale without volume or manner-of-sale restrictions
or current public information requirements pursuant to Rule 144, the Company may require, as a condition of allowing such transfer,
that the Holder or transferee of this Warrant, as the case may be, comply with the provisions of Section 4(a) of the Warrant Exercise
Agreement.

 

e)     
Representation by the Holder. The Holder, by the acceptance hereof, represents and warrants that it is acquiring
this Warrant and, upon any exercise hereof, will acquire the Warrant Shares issuable upon such exercise, for its own account and
not with a view to or for distributing or reselling such Warrant Shares or any part thereof in violation of the Securities Act
or any applicable state securities law, except pursuant to sales registered or exempted under the Securities Act.

 

    	12

    

    

 

Section 5.Miscellaneous.

 

a)     
No Rights as Stockholder Until Exercise. This Warrant does not entitle the Holder to any voting rights, dividends
or other rights as a stockholder of the Company prior to the exercise hereof as set forth in Section 2(d)(i), except as expressly
set forth in Section 3.

 

b)     
Loss, Theft, Destruction or Mutilation of Warrant. The Company covenants that upon receipt by the Company of evidence
reasonably satisfactory to it of the loss, theft, destruction or mutilation of this Warrant or any stock certificate relating to
the Warrant Shares, and in case of loss, theft or destruction, of indemnity or security reasonably satisfactory to it (which, in
the case of the Warrant, shall not include the posting of any bond), and upon surrender and cancellation of such Warrant or stock
certificate, if mutilated, the Company will make and deliver a new Warrant or stock certificate of like tenor and dated as of such
cancellation, in lieu of such Warrant or stock certificate.

 

c)     
Saturdays, Sundays, Holidays, etc. If the last or appointed day for the taking of any action or the expiration of
any right required or granted herein shall not be a Business Day, then, such action may be taken or such right may be exercised
on the next succeeding Business Day.

 

d)    
Authorized Shares.

 

1.                 
During the period the Warrant is outstanding from and after the Initial Exercise Date, the Company covenants that it will
reserve from its authorized and unissued Common Stock a sufficient number of shares to provide for the issuance of the Warrant
Shares upon the exercise of any purchase rights under this Warrant. The Company further covenants that its issuance of this Warrant
shall constitute full authority to its officers who are charged with the duty of issuing the necessary Warrant Shares upon the
exercise of the purchase rights under this Warrant. The Company will take all such reasonable action as may be necessary to assure
that such Warrant Shares may be issued as provided herein without violation of any applicable law or regulation, or of any requirements
of the Trading Market upon which the Common Stock may be listed. The Company covenants that all Warrant Shares which may be issued
upon the exercise of the purchase rights represented by this Warrant will, upon exercise of the purchase rights represented by
this Warrant and payment for such Warrant Shares in accordance herewith, be duly authorized, validly issued, fully paid and nonassessable
and free from all taxes, liens and charges created by the Company in respect of the issue thereof (other than taxes in respect
of any transfer occurring contemporaneously with such issue).

 

2.                 
Except and to the extent as waived or consented to by the Holder, the Company shall not by any action, including, without
limitation, amending its certificate of incorporation or through any reorganization, transfer of assets, consolidation, merger,
dissolution, issue or sale of securities or any other voluntary action, avoid or seek to avoid the observance or performance of
any of the terms of this Warrant, but will at all times in good faith assist in the carrying out of all such terms and in the taking
of all such actions as may be necessary or appropriate to protect the rights of Holder as set forth in this Warrant against impairment.
Without limiting the generality of the foregoing, the Company will (i) not increase the par value of any Warrant Shares above the
amount payable therefor upon such exercise immediately prior to such increase in par value, (ii) take all such action as may be
necessary or appropriate in order that the Company may validly and legally issue fully paid and nonassessable Warrant Shares upon
the exercise of this Warrant and (iii) use commercially reasonable efforts to obtain all such authorizations, exemptions or consents
from any public regulatory body having jurisdiction thereof, as may be, necessary to enable the Company to perform its obligations
under this Warrant.

 

    	13

    

    

 

3.                 
Before taking any action which would result in an adjustment in the number of Warrant Shares for which this Warrant is exercisable
or in the Exercise Price, the Company shall obtain all such authorizations or exemptions thereof, or consents thereto, as may be
necessary from any public regulatory body or bodies having jurisdiction thereof.

 

e)     
Jurisdiction. All questions concerning the construction, validity, enforcement and interpretation of this Warrant
shall be determined in accordance with the provisions of the Warrant Exercise Agreement.

 

f)      
Restrictions. The Holder acknowledges that the Warrant Shares acquired upon the exercise of this Warrant, if not
registered and the Holder does not utilize cashless exercise, will have restrictions upon resale imposed by state and federal securities
laws.

 

g)     
Nonwaiver and Expenses. No course of dealing or any delay or failure to exercise any right hereunder on the part
of Holder shall operate as a waiver of such right or otherwise prejudice the Holder’s rights, powers or remedies, notwithstanding
the fact that all rights hereunder terminate on the Termination Date. If the Company willfully and knowingly fails to comply with
any provision of this Warrant, which results in any material damages to the Holder, the Company shall pay to the Holder such amounts
as shall be sufficient to cover any costs and expenses including, but not limited to, reasonable attorneys’ fees, including
those of appellate proceedings, incurred by the Holder in collecting any amounts due pursuant hereto or in otherwise enforcing
any of its rights, powers or remedies hereunder.

 

h)     
Notices. Any notice, request or other document required or permitted to be given or delivered to the Holder by the
Company shall be delivered in accordance with the notice provisions of the Warrant Exercise Agreement.

 

i)       
Limitation of Liability. No provision hereof, in the absence of any affirmative action by the Holder to exercise
this Warrant to purchase Warrant Shares, and no enumeration herein of the rights or privileges of the Holder, shall give rise to
any liability of the Holder for the purchase price of any Common Stock or as a stockholder of the Company, whether such liability
is asserted by the Company or by creditors of the Company.

 

    	14

    

    

 

j)       
Remedies. The Holder, in addition to being entitled to exercise all rights granted by law, including recovery of
damages, will be entitled to specific performance of its rights under this Warrant. The Company agrees that monetary damages would
not be adequate compensation for any loss incurred by reason of a breach by it of the provisions of this Warrant and hereby agrees
to waive and not to assert the defense in any action for specific performance that a remedy at law would be adequate.

 

k)     
Successors and Assigns. Subject to applicable securities laws, this Warrant and the rights and obligations evidenced
hereby shall inure to the benefit of and be binding upon the successors and permitted assigns of the Company and the successors
and permitted assigns of Holder. The provisions of this Warrant are intended to be for the benefit of any Holder from time to time
of this Warrant and shall be enforceable by the Holder or holder of Warrant Shares.

 

l)       
Amendment. This Warrant may be modified or amended or the provisions hereof waived with the written consent of the
Company and the Holder.

 

m)   
Severability. Wherever possible, each provision of this Warrant shall be interpreted in such manner as to be effective
and valid under applicable law, but if any provision of this Warrant shall be prohibited by or invalid under applicable law, such
provision shall be ineffective to the extent of such prohibition or invalidity, without invalidating the remainder of such provisions
or the remaining provisions of this Warrant.

 

n)     
Headings. The headings used in this Warrant are for the convenience of reference only and shall not, for any purpose,
be deemed a part of this Warrant.

 

********************

(Signature Page Follows)

 

 

 

 

 

 

    	15

    

    

 

IN WITNESS WHEREOF, the Company has caused this
Warrant to be executed by its officer thereunto duly authorized as of the date first above indicated.

 

 

	 	 	AMYRIS, INC.
	 	 	 
	 	 	By: 	 
	 	 	 	Name: Kathleen Valiasek
	 	 	 	Title: Chief Financial Officer
	 	 	 
	 	 	 

 

 

 

 

 

 

 

 

 

    	16

    

    

 

NOTICE OF EXERCISE

 

To:     AMYRIS, INC.

 

(1)  
The undersigned hereby elects to purchase ________ Warrant Shares of the Company pursuant to the terms of the attached Warrant
(only if exercised in full), and tenders herewith payment of the exercise price in full, together with all applicable transfer
taxes, if any.

 

(2)  
Applicable Exercise Price: $

 

(3)  
Payment shall take the form of (check applicable box):

 

[ ] in lawful money of the United States; or

 

[ ] the cancellation of such number of Warrant Shares
as is necessary, in accordance with the formula set forth in subsection 2(c), to exercise this Warrant with respect to the maximum
number of Warrant Shares purchasable pursuant to the cashless exercise procedure set forth in subsection 2(c).

 

(4)  
Please issue said Warrant Shares in the name of the undersigned or in such other name as is specified below:

 

_______________________________

 

 

The Warrant Shares shall be delivered to the following DWAC Account
Number:

 

_______________________________

 

_______________________________

 

_______________________________

 

(4) Accredited Investor. The undersigned
is an “accredited investor” as defined in Regulation D promulgated under the Securities Act of 1933, as amended.

 

[SIGNATURE OF HOLDER]

 

	Name of Investing Entity: 	 
	Signature of Authorized Signatory of Investing Entity:	 
	Name of Authorized Signatory:	 
	Title of Authorized Signatory:	 
	Date:	 
	 	 	 

 

 

 

    

    

    

 

ASSIGNMENT FORM

 

(To assign the foregoing Warrant, execute this form and supply
required information. Do not use this form to purchase shares.)

 

FOR VALUE RECEIVED, the foregoing Warrant and all rights evidenced
thereby are hereby assigned to

 

	Name:	 	 
	 	 	(Please Print)
	 	 	 
	Address:	 	 
	 	 	(Please Print)
	 	 	 
	Phone Number:	 	 
	 	 	 
	Email Address:	 	 
	 	 	 
	Dated:	 _______________ __, ______	 	 
	 	 	 	 
	Holder’s Signature: 	 	 	 
	 	 	 	 
	Holder’s Address:	 	 	 
	 	 	 
	 	 	 

 

 

 

 

 

 

 

 

    

    

    

 

 

Exhibit B

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

    

    

    

 

NOTICE OF EXERCISE

 

To:AMYRIS, INC.

 

(1)  
The undersigned hereby elects to purchase ________ Warrant Shares of the Company pursuant to the terms of the attached Warrant
(only if exercised in full), and tenders herewith payment of the exercise price in full, together with all applicable transfer
taxes, if any.

 

(2)  
Applicable Exercise Price: $

 

(3)  
Payment shall take the form of (check applicable box):

 

[ ] in lawful money of the United States;
or

 

[ ] [the cancellation of such number
of Warrant Shares as is necessary, in accordance with the formula set forth in subsection 2(c), to exercise this Warrant with respect
to the maximum number of Warrant Shares purchasable pursuant to the cashless exercise procedure set forth in subsection 2(c).

 

(4)  
Please issue said Warrant Shares in the name of the undersigned or in such other name as is specified below:

 

_______________________________

 

 

The Warrant Shares shall be delivered to the following DWAC Account Number:

 

_______________________________

 

_______________________________

 

_______________________________

 

(4) Accredited Investor. The undersigned is an “accredited
investor” as defined in Regulation D promulgated under the Securities Act of 1933, as amended.

 

[SIGNATURE OF HOLDER]

 

	Name of Investing Entity: 	 
	Signature of Authorized Signatory of Investing Entity:	 
	Name of Authorized Signatory:	 
	Title of Authorized Signatory:	 
	Date:

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00286-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00286-of-00352.parquet"}]]